Electronic Acknowledgement Receipt

EFS ID:	34094768
Application Number:	16169878
International Application Number:	
Confirmation Number:	9253
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	117796
Filer:	Lorna Lea Tanner/Joannah Laluces
Filer Authorized By:	Lorna Lea Tanner
Attorney Docket Number:	37JD-199059-US10
Receipt Date:	24-OCT-2018
Filing Date:	
Time Stamp:	19:07:38
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Specification	37JD-199059-US10_Specification_Part1.pdf	22150969 83291817dc18355445af23c9e3543081785 9e4fe	no	245

Warnings:

Information:					
2	Specification	37JD-199059-US10_Specification_Part2.pdf	21073466 9a8ebf96a43061c3f941568ad98c66cc682094dc	no	242
Warnings:					
Information:					
3	Specification	37JD-199059-US10_Specification_Part3.pdf	24783609 f294e81d7eaa9679802c54902328675d820b693c	no	249
Warnings:					
Information:					
4	CRF Statement Paper and CRF are the same	37JD-199059-US10_Request_for_Transfer_of_Computer_Readable_Form.pdf	103370 92696b97a79b6574b3624e6055728e26fe5b4fc2	no	1
Warnings:					
Information:					
5	Sequence Listing	37JD-199059-US10_Sequence_Listing.pdf	35784 09de263ec4ff927cdd03ebdbf3ac83a2710d801e	no	2
Warnings:					
Information:					
6	Preliminary Amendment	37JD-199059-US10_Preliminary_Amendment.pdf	99608 d5a078bf757d2c27a08f8b2e59d7225f84f1c3ba	no	3
Warnings:					
Information:					
7	Application Data Sheet	37JD-199059-US10_Application_Data_Sheet.pdf	139916 4aaea45e90c0ff81267d92a9369c053106a0c233	no	7
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
8	Oath or Declaration filed	37JD-199059-US10_Executed_Declarations.pdf	388005 2dab6a9115d828d93a5c85eca78ac4ba04170183	no	4
Warnings:					
Information:					

9	Transmittal of New Application	37JD-199059-US10_Utility_Patent_Application_Transmittal.pdf	106292 3898238de40e36dab3681ce8fc6364397cc0206f	no	1
Warnings:					
Information:					
10	Transmittal Letter	37JD-199059-US10_IDS_Transmittal_Letter.pdf	94867 4d264703fa8c53478e32206c81c8b8ff397eb543	no	2
Warnings:					
Information:					
11	Information Disclosure Statement (IDS) Form (SB08)	37JD-199059-US10_IDS_SB08_Form.pdf	482325 5ed15396f206dced4c68d3a07bbefa131d56bb96	no	36
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
			Total Files Size (in bytes):	69458211	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Field of Invention

The present invention pertains to nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. The invention provides novel chemical compounds, and the use of these compounds alone or in combination with other antiviral agents for treating HCV infection.

Background

Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. There are an estimated 4.5 million infected people in the United States alone, according to the U.S. Center for Disease Control. According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring. Current treatments for HCV infection, which are restricted to immunotherapy

with recombinant interferon-α alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit. Moreover, there is no established vaccine for HCV. Consequently, there is an urgent need for improved therapeutic agents that effectively combat chronic HCV infection.

The HCV virion is an enveloped positive-strand RNA virus with a single oligoribonucleotide genomic sequence of about 9600 bases which encodes a polyprotein of about 3,010 amino acids. The protein products of the HCV gene consist of the structural proteins C, E1, and E2, and the non-structural proteins NS2, NS3, NS4A and NS4B, and NS5A and NS5B. The nonstructural (NS) proteins are believed to provide the catalytic machinery for viral replication. The NS3 protease releases NS5B, the RNA-dependent RNA polymerase from the polyprotein chain. HCV NS5B polymerase is required for the synthesis of a double-stranded RNA from a single-stranded viral RNA that serves as a template in the replication cycle of HCV. Therefore, NS5B polymerase is considered to be an essential component in the HCV replication complex (K. Ishi, et al, *Heptology*, 1999, 29: 1227-1235; V. Lohmann, et al., *Virology*, 1998, 249: 108-118). Inhibition of HCV NS5B polymerase prevents formation of the double-stranded HCV RNA and therefore constitutes an attractive approach to the development of HCV-specific antiviral therapies.

HCV belongs to a much larger family of viruses that share many common features.

Flaviviridae Viruses

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 5 of 739

The Flaviviridae family of viruses comprises at least three distinct genera: *pestiviruses*, which cause disease in cattle and pigs; *flavivruses*, which are the primary cause of diseases such as dengue fever and yellow fever; and *hepaciviruses*, whose sole member is HCV. The flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., *J. Gen. Virol*, 1993,70,37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever (*Fields Virology*, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, PA, 1996, Chapter 31, 931-959). Flaviviruses of global concern that are associated with human disease include the Dengue Hemorrhagic Fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus (Halstead, S. B., *Rev. Infect. Dis.*, 1984, 6, 251-264; Halstead, S. B., *Science*, 239:476-481, 1988; Monath, T. P., *New Eng. J. Med*, 1988, 319, 64 1-643).

The pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. *Adv. Vir. Res.* 1992, 41, 53-98). Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide. BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.J., Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir. Res. 1992, 41, 53-98). Human pestiviruses have not been as extensively characterized as the animal pestiviruses. However, serological surveys indicate considerable pestivirus exposure in humans.

Pestiviruses and hepaciviruses are closely related virus groups within the Flaviviridae family. Other closely related viruses in this family include the GB virus A,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 6 of 739

GB virus A-like agents, GB virus-B and GB virus-C (also called hepatitis G virus, HGV). The hepacivirus group (hepatitis C virus; HCV) consists of a number of closely related but genotypically distinguishable viruses that infect humans. There are at least 6 HCV genotypes and more than 50 subtypes. Due to the similarities between pestiviruses and hepaciviruses, combined with the poor ability of hepaciviruses to grow efficiently in cell culture, bovine viral diarrhea virus (BVDV) is often used as a surrogate to study the HCV virus.

The genetic organization of pestiviruses and hepaciviruses is very similar. These positive stranded RNA viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located within approximately the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF for pestiviruses and hepaciviruses is very similar. For both the pestiviruses and hepaciviruses, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.

The NS proteins of pestiviruses and hepaciviruses share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et al., *Nature,* 1988, 333, 22; Bazan and Fletterick *Virology*

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 7 of 739

, 1989,171,637-639; Gorbalenya et al., *Nucleic Acid Res.*, 1989, 17, 3889-3897). Similarly, the NS5B proteins of pestiviruses and hepaciviruses have the motifs characteristic of RNA-directed RNA polymerases (Koonin, E.V. and Dolja, V.V., *Crir. Rev. Biochem. Molec. Biol.* 1993, 28, 375-430).

The actual roles and functions of the NS proteins of pestiviruses and hepaciviruses in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett, *Virology*, 1991, 184, 341-350; Bartenschlager et al., *J. Virol.* 1993, 67, 3835-3844; Eckart et al. *Biochem. Biophys. Res. Comm.* 1993,192, 399-406; Grakoui et al., *J. Virol.* 1993, 67, 2832-2843; Grakoui et al., *Proc. Natl. Acad Sci. USA* 1993, 90, 10583-10587; Hijikata et al., *J. Virol.* 1993, 67, 4665-4675; Tome et al., *J. Virol.*, 1993, 67, 4017-4026). The NS4A protein, in both cases, acts as a cofactor with the NS3 serine protease (Bartenschlager et al., *J. Virol.* 1994, 68, 5045-5055; Failla et al., *J. Virol.* 1994, 68, 3753-3760; Xu et al., *J. Virol.*, 1997, 71:53 12-5322). The NS3 protein of both viruses also functions as a helicase (Kim et al., *Biochem. Biophys. Res. Comm.*, 1995, 215, 160-166; Jin and Peterson, *Arch. Biochem. Biophys.*, 1995, 323, 47-53; Warrener and Collett, *J. Virol.* 1995, 69,1720-1726). Finally, the NS5B proteins of pestiviruses and hepaciviruses have the predicted RNA-directed RNA polymerases activity (Behrens et al., EMBO, 1996, 15, 12-22; Lechmann et al., *J. Virol.*, 1997, 71, 8416-8428; Yuan et al., *Biochem. Biophys. Res. Comm.* 1997, 232, 231-235; Hagedorn, PCT WO 97/12033; Zhong et al, *J. Virol.*, 1998, 72, 9365-9369).

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 8 of 739

Currently, there are limited treatment options for individuals infected with hepatitis C virus. The current approved therapeutic option is the use of immunotherapy with recombinant interferon-α alone or in combination with the nucleoside analog ribavirin. This therapy is limited in its clinical effectiveness and only 50% of treated patients respond to therapy. Therefore, there is significant need for more effective and novel therapies to address the unmet medical need posed by HCV infection.

A number of potential molecular targets for drug development of direct acting antivirals as anti -HCV therapeutics have now been identified including, but not limited to, the NS2-NS3 autoprotease, the N3 protease, the N3 helicase and the NS5B polymerase. The RNA-dependent RNA polymerase is absolutely essential for replication of the single-stranded, positive sense, RNA genome and this enzyme has elicited significant interest among medicinal chemists.

Inhibitors of HCV NS5B as potential therapies for HCV infection have been reviewed: Tan, S.-L., et al., *Nature Rev. Drug Discov.*, 2002, 1, 867-881; Walker, M.P. et al., *Exp. Opin. Investigational Drugs*, 2003, 12, 1269-1280; Ni, Z-J., et al., *Current Opinion in Drug Discovery and Development*, 2004, 7, 446-459; Beaulieu, P. L., et al., *Current Opinion in Investigational Drugs*, 2004, 5, 838-850; Wu, J., et al., *Current Drug Targets-Infectious Disorders*, 2003, 3, 207-219; Griffith, R.C., et al, *Annual Reports in Medicinal Chemistry*, 2004, 39, 223-237; Carrol, S., et al., *Infectious Disorders-Drug Targets*, 2006, 6, 17-29. The potential for the emergence of resistant HCV strains and the need to identify agents with broad genotype coverage supports the need for continuing efforts to identify novel and more effective nucleosides as HCV NS5B inhibitors.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 9 of 739

Nucleoside inhibitors of NS5B polymerase can act either as a non-natural substrate that results in chain termination or as a competitive inhibitor which competes with nucleotide binding to the polymerase. To function as a chain terminator the nucleoside analog must be taken up by the cell and converted *in vivo* to a triphosphate to compete for the polymerase nucleotide binding site. This conversion to the triphosphate is commonly mediated by cellular kinases which imparts additional structural requirements on a potential nucleoside polymerase inhibitor. Unfortunately, this limits the direct evaluation of nucleosides as inhibitors of HCV replication to cell-based assays capable of *in situ* phosphorylation.


In some cases, the biological activity of a nucleoside is hampered by its poor substrate characteristics for one or more of the kinases needed to convert it to the active triphosphate form. Formation of the monophosphate by a nucleoside kinase is generally viewed as the rate limiting step of the three phosphorylation events. To circumvent the need for the initial phosphorylation step in the metabolism of a nucleoside to the active triphosphate analog, the preparation of stable phosphate prodrugs has been reported. Nucleoside phosphoramidate prodrugs have been shown to be precursors of the active nucleoside triphosphate and to inhibit viral replication when administered to viral infected whole cells (McGuigan, C., et al., *J. Med. Chem.*, 1996, 39, 1748-1753; Valette, G., et al., *J. Med. Chem.*, 1996, 39, 1981-1990; Balzarini, J., et al., *Proc. National Acad Sci USA*, 1996, 93, 7295-7299; Siddiqui, A. Q., et al., *J. Med. Chem.*, 1999, 42, 4122-4128; Eisenberg, E. J., et al., *Nucleosides, Nucleotides and Nucleic Acids*, 2001, 20, 1091-1098; Lee, W.A., et al., *Antimicrobial Agents and Chemotherapy*, 2005, 49, 1898); US 2006/0241064; and WO 2007/095269.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 10 of 739

Also limiting the utility of nucleosides as viable therapeutic agents is their sometimes poor physicochemical and pharmacokinetic properties. These poor properties can limit the intestinal absorption of an agent and limit uptake into the target tissue or cell. To improve on their properties prodrugs of nucleosides have been employed. It has been demonstrated that preparation of nucleoside phosphoramidates improves the systemic absorption of a nucleoside and furthermore, the phosphoramidate moiety of these "pronucleotides" is masked with neutral lipophilic groups to obtain a suitable partition coefficient to optimize uptake and transport into the cell dramatically enhancing the intracellular concentration of the nucleoside monophosphate analog relative to administering the parent nucleoside alone. Enzyme-mediated hydrolysis of the phosphate ester moiety produces a nucleoside monophosphate wherein the rate limiting initial phosphorylation is unnecessary.

SUMMARY OF THE INVENTION

The present invention is directed toward novel phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:



I

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 11 of 739

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 12 of 739

alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 13 of 739

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 14 of 739

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

DEFINITIONS

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

The phrase "as defined herein above" refers to the first definition provided in the Summary of the Invention.

The terms "optional" or "optionally" as used herein means that a subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optional bond" means that the bond may or may not be present, and that the description includes single, double, or triple bonds.

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R appears twice and is defined as "independently carbon or nitrogen", both R's can be carbon, both R's can be nitrogen, or one R' can be carbon and the other nitrogen.

The term "alkenyl" refers to an unsubstituted hydrocarbon chain radical having from 2 to 10 carbon atoms having one or two olefinic double bonds, preferably one olefinic double bond. The term "$C_{2\text{-}N}$ alkenyl" refers to an alkenyl comprising 2 to N

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 15 of 739

carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C_{2-10} alkenyl" refers to an alkenyl comprising 2 to 10 carbon atoms. The term "C_{2-4} alkenyl" refers to an alkenyl comprising 2 to 4 carbon atoms. Examples include, but are not limited to, vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

The term "halogenated alkenyl" refers to an alkenyl comprising at least one of F, Cl, Br, and I.

The term "alkyl" refers to an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 30 carbon atoms. The term "C_{1-M} alkyl" refers to an alkyl comprising 1 to M carbon atoms, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. The term "C_{1-4} alkyl" refers to an alkyl containing 1 to 4 carbon atoms. The term "lower alkyl" denotes a straight or branched chain hydrocarbon residue comprising 1 to 6 carbon atoms. "C_{1-20} alkyl" as used herein refers to an alkyl comprising 1 to 20 carbon atoms. "C_{1-10} alkyl" as used herein refers to an alkyl comprising 1 to 10 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl. The term (ar)alkyl or (heteroaryl)alkyl indicate the alkyl group is optionally substituted by an aryl or a heteroaryl group respectively.


The term "cycloalkyl" refers to an unsubstituted or substituted carbocycle, in which the carbocycle contains 3 to 10 carbon atoms; preferably 3 to 8 carbon atoms; more preferably 3 to 6 carbon atoms (i.e., lower cycloalkyls). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "cycloalkyl alkyl" refers to an additionally unsubstituted or substituted alkyl substituted by a lower cycloalkyl. Examples of cycloalkyl alkyls include, but are not limited to, any one of methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl that is substituted with cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 16 of 739

The term "cycloheteroalkyl" refers to an unsubstituted or substituted heterocycle, in which the heterocycle contains 2 to 9 carbon atoms; preferably 2 to 7 carbon atoms; more preferably 2 to 5 carbon atoms. Examples of cycloheteroalkyls include, but are not limited to, aziridin-2-yl, *N*-C_{1-3}-alkyl-aziridin-2-yl, azetidinyl, *N*-C_{1-3}-alkyl-azetidin-m'-yl, pyrrolidin-m'-yl, *N*-C_{1-3}-alkyl-pyrrolidin-m'-yl, piperidin-m'-yl, and *N*-C_{1-3}-alkyl-piperidin-m'-yl, where m' is 2, 3, or 4 depending on the cycloheteroalkyl. Specific examples of N-C_{1-3}-alkyl-cycloheteroalkyls include, but are not limited to, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-2-yl, N-methyl-piperidin-3-yl, and N-methyl-piperidin-4-yl. In the instance of R^4, the point of attachment between the cycloheteroalkyl ring carbon and the oxygen occurs at any one of m'

The term "heterocycle" refers to an unsubstituted or substituted heterocycle containing carbon, hydrogen, and at least one of N, O, and S, where the C and N can be trivalent or tetravalent, i.e., sp^2- or sp^3-hybridized. Examples of heterocycles include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, imidazole, oxazole, piperazine, etc. In the instance of piperazine, as related to R^{10} for NR'_2, the corresponding opposite nitrogen atom of the piperazinyl is substituted by a lower alkyl represented by the following structure:



Preferably, the opposite nitrogen of the piperazinyl is substituted by a methyl group.

The term "halogenated alkyl" (or "haloalkyl") refers to an unbranched or branched chain alkyl comprising at least one of F, Cl, Br, and I. The term "C_{1-M} haloalkyl" refers to an alkyl comprising 1 to M carbon atoms that comprises at least one of F, Cl, Br, and I, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. "C_{1-3} haloalkyl" refers to a haloalkyl comprising 1 to 3 carbons and at least one of F, Cl, Br, and I. The term "halogenated lower alkyl" (or "lower haloalkyl") refers to a haloalkyl comprising 1 to 6

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 17 of 739

carbon atoms and at least one of F, Cl, Br, and I. Examples include, but are not limited to, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, dibromomethyl, diiodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2-dibromomethyl, 2-2-diiodomethyl, 3-fluoropropyl, 3-chloropropyl, 3-bromopropyl, 2,2,2-trifluoroethyl or 1,1,2,2,2-pentafluoroethyl.

The term "alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond. The term "$C_{2\text{-}N}$ alkynyl" refers to an alkynyl comprising 2 to N carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C $C_{2\text{-}4}$ alkynyl" refers to an alkynyl comprising 2 to 4 carbon atoms. The term "$C_{2\text{-}10}$ alkynyl" refers to an alkynyl comprising 2 to 10 carbons. Examples include, but are limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

The term "halogenated alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond and at least one of F, Cl, Br, and I.

The term "cycloalkyl" refers to a saturated carbocyclic ring comprising 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. The term "$C_{3\text{-}7}$ cycloalkyl" as used herein refers to a cycloalkyl comprising 3 to 7 carbons in the carbocyclic ring.

The term "alkoxy" refers to an -O-alkyl group or an –O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above. Examples of –O-alkyl groups include, but are not limited to, methoxy, ethoxy, *n*-propyloxy, *i*-propyloxy, *n*-butyloxy, *i*-butyloxy, *t*-butyloxy. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "$C_{1\text{-}10}$ alkoxy" refers to an-O-alkyl wherein alkyl is $C_{1\text{-}10}$. Examples of –O-cycloalkyl groups include, but are not limited to, -O-*c*-propyl, -O-*c*-butyl, -O-*c*-pentyl, and –O-*c*-hexyl.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 18 of 739

The term "halogenated alkoxy" refers to an –O-alkyl group in which the alkyl group comprises at least one of F, Cl, Br, and I.

The term "halogenated lower alkoxy" refers to an –O-(lower alkyl) group in which the lower alkyl group comprises at least one of F, Cl, Br, and I.

The term "amino acid" includes naturally occurring and synthetic α, β γ or δ amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In a preferred embodiment, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-argininyl or β-histidinyl. When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of α, β γ or δ glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.

The term "aminoacyl" includes N,N-unsubstituted, N,N-monosubstituted, and N,N-disubstituted derivatives of naturally occurring and synthetic α, β γ or δ amino acyls, where the amino acyls are derived from amino acids. The amino-nitrogen can be substituted or unsubstituted. When the amino-nitrogen is substituted, the nitrogen is either mono- or di-substituted, where the substituent bound to the amino-nitrogen is a lower alkyl or an alkaryl. In the instance of its use for Y, the expression "O(aminoacyl)" is used. It is understood that the C3' carbon of the ribose is bound to the oxygen "O", which is then bound to the carbonyl carbon of the aminoacyl.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 19 of 739

The terms "alkylamino" or "arylamino" refer to an amino group that has one or two alkyl or aryl substituents, respectively.

The term "protected," as used herein and unless otherwise defined, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl, CH_3, CH_2-alkyl, CH_2-alkenyl, CH_2Ph, CH_2-aryl, CH_2O-alkyl, CH_2O-aryl, SO_2-alkyl, SO_2-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

The term "aryl," as used herein, and unless otherwise specified, refers to substituted or unsubstituted phenyl (Ph), biphenyl, or naphthyl, preferably the term aryl refers to substituted or unsubstituted phenyl. The aryl group can be substituted with one or more moieties selected from among hydroxyl, F, Cl, Br, I, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in T.W. Greene and P.G. M. Wuts, "Protective Groups in Organic Synthesis," 3rd ed., John Wiley & Sons, 1999.

The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent, such as benzyl. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.

The term "di(lower alkyl)amino-lower alkyl" refers to a lower alkyl substituted by an amino group that is itself substituted by two lower alkyl groups. Examples include, but are not limited to, $(CH_3)_2NCH_2$, $(CH_3)_2NCH_2CH_2$, $(CH_3)_2NCH_2CH_2CH_2$, etc. The examples above show lower alkyls substituted at the terminus carbon atom with an N,N-dimethyl-amino substituent. These are intended as examples only and are not intended to limit the meaning of the term "di(lower alkyl)amino-lower alkyl" so as to require the same. It is contemplated that the lower alkyl chain can be substituted with an N,N-di(lower alkyl)-amino at any point along the chain, e.g., CH_3CH(N-(lower alkyl)$_2$)CH_2CH_2.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 20 of 739

The term "halo," as used herein, includes chloro, bromo, iodo and fluoro.

The term "acyl" refers to a substituent containing a carbonyl moiety and a non-carbonyl moiety. The carbonyl moiety contains a double-bond between the carbonyl carbon and a heteroatom, where the heteroatom is selected from among O, N and S. When the heteroatom is N, the N is substituted by a lower alkyl. The non-carbonyl moiety is selected from straight, branched, and cyclic alkyl, which includes, but is not limited to, a straight, branched, or cyclic C_{1-20} alkyl, C_{1-10} alkyl, or lower alkyl; alkoxyalkyl, including methoxymethyl; aralkyl, including benzyl; aryloxyalkyl, such as phenoxymethyl; or aryl, including phenyl optionally substituted with halogen (F, Cl, Br, I), hydroxyl, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy, sulfonate esters, such as alkyl or aralkyl sulphonyl, including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. When at least one aryl group is present in the non-carbonyl moiety, it is preferred that the aryl group comprises a phenyl group.

The term "lower acyl" refers to an acyl group in which the non-carbonyl moiety is lower alkyl.

The term "purine" or "pyrimidine" base includes, but is not limited to, adenine, N^6-alkylpurines, N^6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N^6-benzylpurine, N^6-halopurine, N^6-vinylpurine, N^6-acetylenic purine, N^6-acyl purine, N^6-hydroxyalkyl purine, N^6-allcylaminopurine, N^6-thioallcyl purine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C^5-alkylpyrimidines, C^5-benzylpyrimidines, C^5-halopyrimidines, C^5-vinylpyrimidine, C^5-acetylenic pyrimidine, C^5-acyl pyrimidine, C^5-hydroxyalkyl purine, C^5-amidopyrimidine, C^5-cyanopyrimidine, ,C^5-iodopyrimidine, C^6-lodo-pyrimidine, C^5-Br-vinyl pyrimidine, C^6-Br-vinyl pyrimidine, C^5-nitropyrimidine, C^5-amino-pyrimidine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 21 of 739


hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, and *t*-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.

The term "tautomerism" and "tautomers" have their accepted plain meanings.

The term "P*" means that the phosphorous atom is chiral and that it has a corresponding Cahn-Ingold-Prelog designation of "R" or "S" which have their accepted plain meanings. It is contemplated that compounds of the formula I are racemic because the chirality at phosphorous. Applicants contemplate use of the racemate and/or the resolved enantiomers. In some instances, an asterisk does not appear next to the phosphoroamidate phosphorous atom. In these instances, it is understood that the phosphorous atom is chiral and that one of ordinary skill understands this to be so unless the substituents bound to the phosphorous exclude the possibility of chirality at phosphorous, such as in $P(O)Cl_3$.

DETAILED DESCRIPTION OF THE INVENTION

An aspect of the invention is directed to a compound, its salts, hydrates, solvates, crystalline forms, and the like represented by formula I:



wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 22 of 739

optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 23 of 739

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 24 of 739



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 25 of 739

halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

As can be appreciated from the structure represented by formula **I** above, there are myriad ways to express the several embodiments and aspects of each embodiment of the present invention. As seen below, the inventors have disclosed certain embodiments directed to the compound of formula **I**, each having several aspects, based on the identity of the modified purine or pyrimidine base. This is not intended to be an explicit or implicit admission that the three embodiments are independent or distinct nor should it be interpreted as such. Rather, it is intended to convey information so that the full breadth of the present invention can be understood. Furthermore, the following embodiments, and aspects thereof, are not meant to be limiting on the full breadth of the invention as recited by the structure of formula **I**.

A first embodiment of the invention is directed to a compound represented by formula **I-1**:



I-1

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 26 of 739

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 27 of 739

Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)-amino, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), O$S(O)_2$(C_{1-4} acyl), O$S(O)_2$(C_{1-4} alkyl), O$S(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4}

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 28 of 739

alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A first aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'-OH)-Ph)$, CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'-OH)-Ph)$, or CH_2SH and R^{3b} is H;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 29 of 739

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, vinyl, N_3, CN, Cl, Br, F, I, O(C_{1-6} acyl), O(C_{1-4} alkyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-4} haloalkyl, O(aminoacyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, or N(C_{1-4} acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A second aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 30 of 739

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a C_{1-3} alkyl, a C_{1-3} alkoxy, F, Cl, Br, I, nitro, cyano, and a C_{1-3} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 31 of 739

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A third aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 32 of 739

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;


(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl'; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fourth aspect of the first embodiment is directed to a compound represented by formula **I-2**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 33 of 739



I-2

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 34 of 739

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and and $N(C(O)(CH_2)_sCH_3$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fifth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 35 of 739

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A sixth aspect of the first embodiment is directed to a compound represented by formula **I-2**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 36 of 739

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkyl optionally substituted with a lower alkyl, alkoxy or halogen, $C_{1\text{-}10}$ haloalkyl, $C_{3\text{-}10}$ cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, or N_3, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3\text{-}q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1\text{-}20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1\text{-}20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A seventh aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 37 of 739

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

An eighth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 38 of 739

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;


(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A second embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **b** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, R^7, and $R^8$are defined in the Summary of the Invention section above.

A first aspect of the second embodiment is directed to a compound represented by

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 39 of 739

formula **I-3**



I-3

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 40 of 739

$(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, -CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 41 of 739

$S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-4}$ acyl)$_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The second aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi)

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 42 of 739

R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkyl optionally substituted with a lower alkyl, alkoxy or halogen, $C_{1\text{-}10}$ haloalkyl, $C_{3\text{-}10}$ cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, $C_{1\text{-}4}$ alkyl, vinyl, N_3, CN, Cl, Br, F, I, $O(C_{1\text{-}6}$ acyl), $O(C_{1\text{-}4}$ alkyl), NH_2, $NH(C_{1\text{-}4}$ alkyl), $NH(C_{2\text{-}4}$ alkenyl), $NH(C_{2\text{-}4}$ alkynyl), $NH(C_{1\text{-}4}$ acyl), $N(C_{1\text{-}4}$ alkyl)$_2$, $N(C_{1\text{-}18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $OC(O)O(C_{1\text{-}4}$ alkyl), $OC(O)O(C_{1\text{-}4}$ alkyl), $OC(O)O(C_{2\text{-}4}$ alkynyl), $OC(O)O(C_{2\text{-}4}$ alkenyl), $OC_{1\text{-}10}$ haloalkyl, O(aminoacyl), $O(C_{1\text{-}4}$ acyl), $O(C_{1\text{-}4}$ alkyl), $O(C_{2\text{-}4}$ alkenyl), $S(C_{1\text{-}4}$ acyl), $S(C_{1\text{-}4}$ alkyl), $S(C_{2\text{-}4}$ alkynyl), $S(C_{2\text{-}4}$ alkenyl), $SO(C_{1\text{-}4}$ acyl), $SO(C_{1\text{-}4}$ alkyl), $SO(C_{2\text{-}4}$ alkynyl), $SO(C_{2\text{-}4}$ alkenyl), $SO_2(C_{1\text{-}4}$ acyl), $SO_2(C_{1\text{-}4}$ alkyl), $SO_2(C_{2\text{-}4}$ alkynyl), $SO_2(C_{2\text{-}4}$ alkenyl), $OS(O)_2(C_{1\text{-}4}$ acyl), $OS(O)_2(C_{1\text{-}4}$ alkyl), $OS(O)_2(C_{2\text{-}4}$ alkenyl), NH_2, $NH(C_{1\text{-}4}$ alkyl), $NH(C_{2\text{-}4}$ alkenyl), $NH(C_{2\text{-}4}$ alkynyl), $NH(C_{1\text{-}4}$ acyl), $N(C_{1\text{-}4}$ alkyl)$_2$, $N(C_{1\text{-}4}$ acyl)$_2$;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 43 of 739

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, wherein R' is a $C_{1\text{-}20}$ alkyl; a $C_{1\text{-}20}$ cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The third aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a $C_{1\text{-}3}$ alkyl, a $C_{1\text{-}3}$ alkoxy, F, Cl, Br, I, nitro, cyano, and a $C_{1\text{-}3}$ haloalkyl;

(b) R^2 is hydrogen, CH_3, R^{3a} or R^{3b} and R^2 together are $(CH_2)_3$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b} are as defined herein;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or $C_{1\text{-}6}$ alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 44 of 739

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The fourth aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 45 of 739

$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The fifth aspect of the second embodiment is directed to a compound represented by formula **I-4**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 46 of 739



I-4

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 47 of 739

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl,

The sixth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 48 of 739

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The seventh aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 49 of 739

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;

The eighth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The ninth aspect of the second embodiment is directed to a compound represented by formula **I-4**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 50 of 739

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;


(h) Y is OH, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

A third embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **c** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, Z, R^{10}, R^{11}, and R^{12} are defined in the Summary of the Invention section above; with the proviso that R^{11} is not H.

A first aspect of the third embodiment is directed to a compound represented by formula **I-5**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 51 of 739



I-5

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 52 of 739

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is from H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 53 of 739

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 54 of 739

Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A second aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 55 of 739

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 56 of 739

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A fourth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 57 of 739

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 58 of 739

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A sixth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 59 of 739

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A seventh aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 60 of 739

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

An eighth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 61 of 739

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A ninth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 62 of 739

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, or N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R';


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'.

A tenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 63 of 739



I-6

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 64 of 739

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 65 of 739

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'.

An eleventh aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 66 of 739

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A twelvth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 67 of 739

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is a H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$.

A thirteenth aspect of the third embodiment is directed to a compound represented

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 68 of 739

by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 69 of 739

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A fourteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 70 of 739

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 71 of 739

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 72 of 739

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2$H, or CH=$CHCO_2$R'.

An sixteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 73 of 739

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A seventeenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 74 of 739

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

An eighteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 75 of 739

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A nineteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 76 of 739

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 77 of 739

A fourth embodiment of the invention is directed to a compound represented by formula I in which the base is a structure represented by formula **c** above, where R^{11} is H and R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

A first aspect of the fourth embodiment is directed to a compound represented by formula **I-7**



I-7

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 78 of 739

$(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 79 of 739

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 80 of 739

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A second aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 81 of 739

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 82 of 739

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

A fourth aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 83 of 739

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fifth aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 84 of 739

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

A sixth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 85 of 739



I-8

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 86 of 739

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 87 of 739

$OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2$R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2$R'; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

A seventh aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 88 of 739

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

An eighth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 89 of 739

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl , N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

A ninth aspect of the fourth embodiment is directed to a compound represented by

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 90 of 739

formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 91 of 739

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

A tenth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 92 of 739


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fifth embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **d** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

The first aspect of the fifth embodiment is directed to a compound represented by formula **I-9**



I-9

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 93 of 739

alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 94 of 739

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$.

A second aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 95 of 739

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

A third aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 96 of 739

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 N_3, OCH_3, or $OC(O)CH_3$;

A fourth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 97 of 739

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A fifth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A sixth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 98 of 739



I-10

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 99 of 739

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

A seventh aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 100 of 739

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3; and

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3.

An eighth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

A ninth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 101 of 739

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A tenth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 102 of 739

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;


(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$.

The following tables contain numeric identifiers associated with various substituent designators that should be viewed in light of the accompanying structure. These structures are contemplated species of the various aspects of the disclosed embodiments and are not intended to be limiting on full breadth of the contemplated compound represented by the structure of formula **I**. However, it is contemplated that any one of the exemplified nucleoside bases can be used in combination with any one of contemplated species that specify a particular combination of R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y. In each of the presented tables, the phosphoramidate substituent containing the substituents R^{3a} and R^{3b} are depicted without reference to stereochemical structure (*cf.* structures **I-1**, **I-3**, **I-5**, **I-7**, and **I-9** above). It is contemplated that the compounds recited below embody compounds in which R^{3a} projects toward the viewer while R^{3b} projects away from the viewer (cf. structures **I-2**, **I-4**, **I-6**, **I-8**, and **I-10**). Moreover, it is contemplated that the compounds recited below also embody compounds in which R^{3a} projects away from the viewer while R^{3b} projects towards the viewer. Not meant to be limiting, however, it is contemplated that preferred compounds are those in which R^{3a} projects towards the viewer and R^{3b} projects away from the viewer such that the natural L-amino acid (S)-configuration is presented. Additionally, the inventors recognize that the phosphorus atom of the phosphoramidate moiety is another source of chirality. Although the structures below do not specifically depict chirality at phosphorus, the inventors recognize that stereochemical configurations are possible such that in a staggered (or zig-zag) line structure the oxo-substitutent projects towards the viewer

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 103 of 739

while the OR^1 substitutent projects away from the viewer, and vice versa, i.e., where the Cahn-Ingold-Prelog stereochemical designation of phosphorous is either R or S. Therefore, the structures below include all possible stereochemical configurations possible for phosphorus.



II

Table II-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-1-1	CH_3	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-8	CH_3	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-1	Et	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-2	Et	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 104 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-8	Et	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-1	Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 105 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-8	Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 106 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 107 of 739

Table II-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-11-1	CH_3	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-2	CH_3	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-8	CH_3	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-12-1	Et	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-2	Et	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-8	Et	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-13-1	^{i}Pr	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-8	^{i}Pr	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 108 of 739

Table II-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-14-1	^{t}Bu	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-8	^{t}Bu	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-15-1	Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-2	Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-8	Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 109 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-17-1	p-F-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-8	p-F-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 110 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-20-1	p-I-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-8	p-I-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-1	Et	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 111 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-8	Et	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 112 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 113 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-2	p-Cl-Ph	H	H	CH_3	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-5	p-Cl-Ph	H	H	CH_2Ph	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-28-8	p-Cl-Ph	*	H	*	^iPr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-29-1	p-Br-Ph	H	H	H	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-2	p-Br-Ph	H	H	CH_3	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-5	p-Br-Ph	H	H	CH_2Ph	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-29-8	p-Br-Ph	*	H	*	^iPr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-30-1	p-I-Ph	H	H	H	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-2	p-I-Ph	H	H	CH_3	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-5	p-I-Ph	H	H	CH_2Ph	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	CH_3	OH	OH	H	H	NH_2
II-30-8	p-I-Ph	*	H	*	^iPr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-31.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 114 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-32-1	Et	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-8	Et	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 115 of 739

Table II-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 116 of 739

Table II-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 117 of 739

Table II-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-41-1	CH_3	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-8	CH_3	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-42-1	Et	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-2	Et	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-8	Et	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 118 of 739

Table II-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-45-1	Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-2	Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-8	Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 119 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 120 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 121 of 739



III

Table III-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 122 of 739

Table III-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 123 of 739

Table III-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 124 of 739

Table III-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 125 of 739

Table III-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-12-1	Et	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-8	Et	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 126 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-15-1	Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-8	Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 127 of 739

Table III-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 128 of 739

Table III-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 129 of 739

Table III-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 130 of 739

Table III-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 131 of 739

Table III-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 132 of 739

Table III-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 133 of 739

Table III-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 134 of 739

Table III-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 135 of 739

Table III-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-42-1	Et	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-8	Et	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 136 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 137 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 138 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



IV

Table IV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-1	CH_3	H	H	H	CH_3	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 139 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-8	CH_3	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-2-1	Et	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-8	Et	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 140 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-5-1	Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-8	Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 141 of 739

Table IV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 142 of 739

Table IV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-11-1	CH_3	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-11-8	CH_3	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-12-1	Et	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-12-2	Et	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-12-8	Et	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 143 of 739

Table IV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 144 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-15-1	Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-15-2	Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-15-8	Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 145 of 739

Table IV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 146 of 739

Table IV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 147 of 739

Table IV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 148 of 739

Table IV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 149 of 739

Table IV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 150 of 739

Table IV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 151 of 739

Table IV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 152 of 739

Table IV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-41-1	CH_3	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-41-8	CH_3	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 153 of 739

Table IV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-42-1	Et	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-42-2	Et	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-42-8	Et	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 154 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-45-1	Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-45-8	Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 155 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table IV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 156 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



V

Table V-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-1-1	CH_3	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-1-8	CH_3	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-1	Et	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 157 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-2-8	Et	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 158 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-5-1	Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-5-8	Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 159 of 739

Table V-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 160 of 739

Table V-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-11-1	CH_3	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-11-8	CH_3	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-12-1	Et	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-12-2	Et	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-12-8	Et	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 161 of 739

Table V-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-15-1	Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-15-2	Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-15-8	Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 162 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 163 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 164 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 165 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 166 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-28-2	p-Cl-Ph	H	H	CH_3	^iPr	H	H	F	OH	H	H	NH_2
V-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-28-5	p-Cl-Ph	H	H	CH_2Ph	^iPr	H	H	F	OH	H	H	NH_2
V-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^iPr	H	H	F	OH	H	H	NH_2
V-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	H	F	OH	H	H	NH_2
V-28-8	p-Cl-Ph	*	H	*	^iPr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-29-1	p-Br-Ph	H	H	H	^iPr	H	H	F	OH	H	H	NH_2
V-29-2	p-Br-Ph	H	H	CH_3	^iPr	H	H	F	OH	H	H	NH_2
V-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-29-5	p-Br-Ph	H	H	CH_2Ph	^iPr	H	H	F	OH	H	H	NH_2
V-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^iPr	H	H	F	OH	H	H	NH_2
V-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	H	F	OH	H	H	NH_2
V-29-8	p-Br-Ph	*	H	*	^iPr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-30-1	p-I-Ph	H	H	H	^iPr	H	H	F	OH	H	H	NH_2
V-30-2	p-I-Ph	H	H	CH_3	^iPr	H	H	F	OH	H	H	NH_2
V-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^iPr	H	H	F	OH	H	H	NH_2
V-30-5	p-I-Ph	H	H	CH_2Ph	^iPr	H	H	F	OH	H	H	NH_2
V-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^iPr	H	H	F	OH	H	H	NH_2
V-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^iPr	H	H	F	OH	H	H	NH_2
V-30-8	p-I-Ph	*	H	*	^iPr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-31.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 167 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 168 of 739

Table V-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 169 of 739

Table V-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 170 of 739

Table V-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-41-1	CH_3	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-41-8	CH_3	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-42-1	Et	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-42-2	Et	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-42-8	Et	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 171 of 739

Table V-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-45-1	Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-45-8	Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 172 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 173 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 174 of 739



VI

Table VI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H
VI-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H
VI-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 175 of 739

Table VI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H
VI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H
VI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 176 of 739

Table VI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 177 of 739

Table VI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-11-1	CH_3	H	H	H	Et	H	F	H	OH	H	H
VI-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H
VI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 178 of 739

Table VI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-12-1	Et	H	H	H	Et	H	F	H	OH	H	H
VI-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H
VI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-12-8	Et	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH	H	H
VI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH	H	H
VI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H
VI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H
VI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 179 of 739

Table VI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H
VI-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 180 of 739

Table VI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 181 of 739

Table VI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 182 of 739

Table VI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 183 of 739

Table VI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 184 of 739

Table VI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 185 of 739

Table VI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 186 of 739

Table VI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 187 of 739

Table VI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-41-1	CH_3	H	H	H	Bz	H	F	H	OH	H	H
VI-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-41-8	CH_3	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 188 of 739

Table VI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-42-1	Et	H	H	H	Bz	H	F	H	OH	H	H
VI-42-2	Et	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-42-8	Et	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH	H	H
VI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH	H	H
VI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 189 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-45-1	Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-45-8	Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 190 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table VI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 191 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



VII

Table VII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 192 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-5.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 193 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 194 of 739

Table VII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 195 of 739

Table VII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-11-1	CH_3	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-12-1	Et	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-12-8	Et	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 196 of 739

Table VII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 197 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 198 of 739

Table VII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 199 of 739

Table VII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 200 of 739

Table VII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 201 of 739

Table VII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 202 of 739

Table VII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 203 of 739

Table VII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 204 of 739

Table VII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 205 of 739

Table VII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H	NH_2
VII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-41-1	CH_3	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-41-8	CH_3	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-42-1	Et	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-42-2	Et	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-42-8	Et	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 206 of 739

Table VII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-45-1	Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-45-8	Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 207 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 208 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH	H	H	NH_2
VII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H	NH_2
VII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H	NH_2
VII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H	NH_2
VII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H	NH_2
VII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H	NH_2
VII-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 209 of 739



VIII

Table VIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-1-1	CH_3	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-1-8	CH_3	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-2-1	Et	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-2-2	Et	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-2-8	Et	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 210 of 739

Table VIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-5-1	Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-5-8	Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 211 of 739

Table VIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 212 of 739

Table VIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H
VIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H
VIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H
VIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H
VIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H
VIII-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-11-1	CH_3	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-11-2	CH_3	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-11-8	CH_3	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 213 of 739

Table VIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-12-1	Et	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-12-2	Et	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-12-8	Et	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-13-1	^{i}Pr	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-13-8	^{i}Pr	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-14-1	^{t}Bu	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-14-8	^{t}Bu	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 214 of 739

Table VIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-15-1	Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-15-2	Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-15-8	Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-17-1	p-F-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-17-8	p-F-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 215 of 739

Table VIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-20-1	p-I-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H
VIII-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H
VIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H
VIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H
VIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H
VIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H
VIII-20-8	p-I-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 216 of 739

Table VIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-22-1	Et	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-22-8	Et	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 217 of 739

Table VIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 218 of 739

Table VIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 219 of 739

Table VIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H
VIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-32-1	Et	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-32-8	Et	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 220 of 739

Table VIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 221 of 739

Table VIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 222 of 739

Table VIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H
VIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-41-1	CH_3	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-41-8	CH_3	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 223 of 739

Table VIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-42-1	Et	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-42-2	Et	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-42-8	Et	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 224 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-45-1	Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-45-2	Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-45-8	Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 225 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H
VIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table VIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H
VIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H
VIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H
VIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 226 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H
VIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H
VIII-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



IX

Table IX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 227 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-5.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 228 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 229 of 739

Table IX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H
IX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H
IX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H
IX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H
IX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H
IX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H
IX-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 230 of 739

Table IX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH	H	H
IX-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-12-1	Et	H	H	H	Et	H	CH_3	F	OH	H	H
IX-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-12-8	Et	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH	H	H
IX-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 231 of 739

Table IX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH	H	H
IX-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-15-1	Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-15-8	Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 232 of 739

Table IX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 233 of 739

Table IX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH	H	H
IX-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H
IX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H
IX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H
IX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H
IX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H
IX-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 234 of 739

Table IX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 235 of 739

Table IX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 236 of 739

Table IX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H
IX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 237 of 739

Table IX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 238 of 739

Table IX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 239 of 739

Table IX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H
IX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 240 of 739

Table IX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-42-1	Et	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-42-8	Et	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 241 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 242 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 243 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
IX-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H
IX-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H
IX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H
IX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H
IX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H
IX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H
IX-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



X

Table X-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-1-1	CH_3	H	H	H	CH_3	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 244 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-1-8	CH_3	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-2-1	Et	H	H	H	CH_3	H	F	F	OH	H	H
X-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-2-8	Et	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH	H	H
X-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 245 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH	H	H
X-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-5-1	Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-5-8	Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 246 of 739

Table X-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 247 of 739

Table X-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH	H	H
X-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H
X-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H
X-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H
X-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H
X-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H
X-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-11-1	CH_3	H	H	H	Et	H	F	F	OH	H	H
X-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH	H	H
X-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-11-8	CH_3	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-12-1	Et	H	H	H	Et	H	F	F	OH	H	H
X-12-2	Et	H	H	CH_3	Et	H	F	F	OH	H	H
X-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-12-8	Et	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 248 of 739

Table X-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH	H	H
X-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH	H	H
X-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH	H	H
X-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH	H	H
X-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-15-1	Ph	H	H	H	Et	H	F	F	OH	H	H
X-15-2	Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-15-8	Ph	*	H	*	Et	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 249 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH	H	H
X-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH	H	H
X-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH	H	H
X-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 250 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH	H	H
X-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH	H	H
X-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H
X-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H
X-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H
X-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H
X-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
X-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH	H
X-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH	H
X-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H
X-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H
X-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H
X-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H
X-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H
X-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 251 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 252 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 253 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-30.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 254 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H
X-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H
X-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H
X-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H
X-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H
X-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H
X-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 255 of 739

Table X-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 256 of 739

Table X-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 257 of 739

Table X-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H
X-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H
X-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H
X-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H
X-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H
X-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H
X-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-41-1	CH_3	H	H	H	Bz	H	F	F	OH	H	H
X-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH	H	H
X-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-41-8	CH_3	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 258 of 739

Table X-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-42-1	Et	H	H	H	Bz	H	F	F	OH	H	H
X-42-2	Et	H	H	CH_3	Bz	H	F	F	OH	H	H
X-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-42-8	Et	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH	H	H
X-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH	H	H
X-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH	H	H
X-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH	H	H
X-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 259 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-45-1	Ph	H	H	H	Bz	H	F	F	OH	H	H
X-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-45-8	Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 260 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table X-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H
X-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table X-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH	H	H
X-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H
X-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H
X-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 261 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
X-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H
X-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H
X-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XI

Table XI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-1-1	CH_3	H	H	H	CH_3	H	H	F	OH	H	H
XI-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-1-8	CH_3	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-2-1	Et	H	H	H	CH_3	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 262 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-2-8	Et	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH	H	H
XI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH	H	H
XI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-5.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 263 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-5-1	Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-5-8	Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 264 of 739

Table XI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH	H	H
XI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H
XI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H
XI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H
XI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H
XI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H
XI-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 265 of 739

Table XI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-11-1	CH_3	H	H	H	Et	H	H	F	OH	H	H
XI-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH	H	H
XI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-11-8	CH_3	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-12-1	Et	H	H	H	Et	H	H	F	OH	H	H
XI-12-2	Et	H	H	CH_3	Et	H	H	F	OH	H	H
XI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-12-8	Et	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH	H	H
XI-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH	H	H
XI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 266 of 739

Table XI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH	H	H
XI-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH	H	H
XI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-15-1	Ph	H	H	H	Et	H	H	F	OH	H	H
XI-15-2	Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-15-8	Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 267 of 739

Table XI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 268 of 739

Table XI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH	H	H
XI-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH	H	H
XI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H
XI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H
XI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H
XI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H
XI-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 269 of 739

Table XI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 270 of 739

Table XI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 271 of 739

Table XI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H
XI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H
XI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H
XI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H
XI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H
XI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H
XI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 272 of 739

Table XI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 273 of 739

Table XI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 274 of 739

Table XI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H
XI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H
XI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H
XI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H
XI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H
XI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H
XI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 275 of 739

Table XI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-41-1	CH_3	H	H	H	Bz	H	H	F	OH	H	H
XI-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-41-8	CH_3	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-42-1	Et	H	H	H	Bz	H	H	F	OH	H	H
XI-42-2	Et	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-42-8	Et	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH	H	H
XI-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 276 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH	H	H
XI-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-45-1	Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-45-8	Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 277 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 278 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XI-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH	H	H
XI-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H
XI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H
XI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H
XI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H
XI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H
XI-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XII

Table XII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-1-1	CH_3	H	H	H	CH_3	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 279 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-1-2	CH_3	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-1-8	CH_3	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-2-1	Et	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-2-2	Et	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-2-5	Et	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-2-8	Et	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-3-1	^{i}Pr	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-3-2	^{i}Pr	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-3-8	^{i}Pr	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 280 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-4-1	^{t}Bu	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-4-8	^{t}Bu	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-5-1	Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-5-2	Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-5-8	Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-6-1	p-Me-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-6-8	p-Me-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 281 of 739

Table XII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-7-1	p-F-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-7-20	p-F-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-9-1	p-Br-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-9-20	p-Br-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 282 of 739

Table XII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-10-1	p-I-Ph	H	H	H	CH_3	N_3	F	F	OH	H	H
XII-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	F	F	OH	H	H
XII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	F	OH	H	H
XII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	F	F	OH	H	H
XII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	F	OH	H	H
XII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	F	OH	H	H
XII-10-8	p-I-Ph	*	H	*	CH_3	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-11-1	CH_3	H	H	H	Et	N_3	F	F	OH	H	H
XII-11-2	CH_3	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-11-5	CH_3	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-11-8	CH_3	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-12-1	Et	H	H	H	Et	N_3	F	F	OH	H	H
XII-12-2	Et	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-12-5	Et	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-12-8	Et	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 283 of 739

Table XII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-13-1	^{i}Pr	H	H	H	Et	N_3	F	F	OH	H	H
XII-13-2	^{i}Pr	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-13-5	^{i}Pr	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-13-8	^{i}Pr	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-14-1	^{t}Bu	H	H	H	Et	N_3	F	F	OH	H	H
XII-14-2	^{t}Bu	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-14-8	^{t}Bu	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 284 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-15-1	Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-15-2	Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-15-5	Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-15-8	Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-16-1	p-Me-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-16-8	p-Me-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-17-1	p-F-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-17-2	p-F-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-17-8	p-F-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 285 of 739

Table XII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-18-1	p-Cl-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-18-8	p-Cl-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-19-1	p-Br-Ph	H	H	H	Et	N_3	F	F	OH	H	H
XII-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	F	F	OH	H	H
XII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H	H
XII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H	H
XII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H	H
XII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H	H
XII-19-8	p-Br-Ph	*	H	*	Et	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XII-20-1	p-I-Ph	H	H	H	Et	N_3	F	F	OH	H
XII-20-2	p-I-Ph	H	H	CH_3	Et	N_3	F	F	OH	H
XII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	F	OH	H
XII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	F	OH	H
XII-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	F	F	OH	H
XII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	F	OH	H
XII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	F	OH	H
XII-20-8	p-I-Ph	*	H	*	Et	N_3	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 286 of 739

Table XII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-21-1	CH_3	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-21-8	CH_3	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-22-1	Et	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-22-2	Et	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-22-8	Et	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 287 of 739

Table XII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-25-1	Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-25-8	Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 288 of 739

Table XII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 289 of 739

Table XII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	F	F	OH	H	H
XII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	F	F	OH	H	H
XII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	F	OH	H	H
XII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	F	OH	H	H
XII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	F	OH	H	H
XII-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-31-1	CH_3	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-31-8	CH_3	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-32-1	Et	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-32-2	Et	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-32-8	Et	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 290 of 739

Table XII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-35-1	Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-35-8	Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 291 of 739

Table XII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 292 of 739

Table XII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	F	F	OH	H	H
XII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	F	F	OH	H	H
XII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	F	OH	H	H
XII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	F	OH	H	H
XII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	F	OH	H	H
XII-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-41-1	CH_3	H	H	H	Bz	N_3	F	F	OH	H	H
XII-41-2	CH_3	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-41-8	CH_3	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 293 of 739

Table XII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-42-1	Et	H	H	H	Bz	N_3	F	F	OH	H	H
XII-42-2	Et	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-42-5	Et	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-42-8	Et	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-43-1	^{i}Pr	H	H	H	Bz	N_3	F	F	OH	H	H
XII-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-43-8	^{i}Pr	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-44-1	^{t}Bu	H	H	H	Bz	N_3	F	F	OH	H	H
XII-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-44-8	^{t}Bu	*	H	*	Bz	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 294 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-45-1	Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-45-2	Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-45-5	Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-45-8	Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-46-1	p-Me-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-46-8	p-Me-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-47-1	p-F-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 295 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-47-8	p-F-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-48-1	p-Cl-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-48-8	p-Cl-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-49-1	p-Br-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H
XII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-49-8	p-Br-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-50-1	p-I-Ph	H	H	H	Bz	N_3	F	F	OH	H	H
XII-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	F	F	OH	H	H
XII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	F	OH	H	H
XII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 296 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	F	OH	H	H
XII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	F	OH	H	H
XII-50-8	p-I-Ph	*	H	*	Bz	N_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XIII

Table XIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-1-1	CH_3	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-1-2	CH_3	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-1-8	CH_3	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-2-1	Et	H	H	H	CH_3	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 297 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-2-2	Et	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-2-5	Et	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-2-8	Et	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-3-1	^{i}Pr	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-3-2	^{i}Pr	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-3-8	^{i}Pr	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-4-1	^{t}Bu	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-4-8	^{t}Bu	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-5.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 298 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-5-1	Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-5-2	Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-5-8	Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-6-1	p-Me-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-6-8	p-Me-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-7-1	p-F-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-7-20	p-F-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 299 of 739

Table XIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-9-1	p-Br-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-9-20	p-Br-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-10-1	p-I-Ph	H	H	H	CH_3	N_3	H	F	OH	H	H
XIII-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	H	F	OH	H	H
XIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	H	F	OH	H	H
XIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	H	F	OH	H	H
XIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	H	F	OH	H	H
XIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	H	F	OH	H	H
XIII-10-8	p-I-Ph	*	H	*	CH_3	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 300 of 739

Table XIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-11-1	CH_3	H	H	H	Et	N_3	H	F	OH	H	H
XIII-11-2	CH_3	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-11-5	CH_3	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-11-8	CH_3	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-12-1	Et	H	H	H	Et	N_3	H	F	OH	H	H
XIII-12-2	Et	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-12-5	Et	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-12-8	Et	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-13-1	^{i}Pr	H	H	H	Et	N_3	H	F	OH	H	H
XIII-13-2	^{i}Pr	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-13-8	^{i}Pr	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 301 of 739

Table XIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-14-1	^{t}Bu	H	H	H	Et	N_3	H	F	OH	H	H
XIII-14-2	^{t}Bu	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-14-8	^{t}Bu	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-15-1	Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-15-2	Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-15-5	Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-15-8	Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-16-1	p-Me-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-16-8	p-Me-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 302 of 739

Table XIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-17-1	p-F-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-17-2	p-F-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-17-8	p-F-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-18-1	p-Cl-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-18-8	p-Cl-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-19-1	p-Br-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-19-8	p-Br-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 303 of 739

Table XIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-20-1	p-I-Ph	H	H	H	Et	N_3	H	F	OH	H	H
XIII-20-2	p-I-Ph	H	H	CH_3	Et	N_3	H	F	OH	H	H
XIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	H	F	OH	H	H
XIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	H	F	OH	H	H
XIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	H	F	OH	H	H
XIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	H	F	OH	H	H
XIII-20-8	p-I-Ph	*	H	*	Et	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-21-1	CH_3	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-21-8	CH_3	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-22-1	Et	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-2	Et	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-22-8	Et	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 304 of 739

Table XIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-25-1	Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-25-8	Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 305 of 739

Table XIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 306 of 739

Table XIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	H	F	OH	H	H
XIII-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-31-1	CH_3	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-31-8	CH_3	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 307 of 739

Table XIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-32-1	Et	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-2	Et	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-32-8	Et	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 308 of 739

Table XIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-35-1	Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-35-8	Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 309 of 739

Table XIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	H	F	OH	H	H
XIII-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 310 of 739

Table XIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-41-1	CH_3	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-41-2	CH_3	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-41-8	CH_3	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-42-1	Et	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-42-2	Et	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-42-5	Et	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-42-8	Et	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-43-1	^{i}Pr	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-43-8	^{i}Pr	*	H	*	Bz	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 311 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-44-1	^{t}Bu	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-44-8	^{t}Bu	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-45-1	Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-45-2	Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-45-5	Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-45-8	Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-46-1	p-Me-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 312 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-46-8	p-Me-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-47-1	p-F-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-47-8	p-F-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-48-1	p-Cl-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-48-8	p-Cl-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-49-1	p-Br-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 313 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-49-8	p-Br-Ph	*	H	*	Bz	N_3	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIII-50-1	p-I-Ph	H	H	H	Bz	N_3	H	F	OH	H	H
XIII-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	H	F	OH	H	H
XIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	H	F	OH	H	H
XIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	H	F	OH	H	H
XIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	H	F	OH	H	H
XIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	H	F	OH	H	H
XIII-50-8	p-I-Ph	*	H	*	Bz	N_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XIV

Table XIV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-1-1	CH_3	H	H	H	CH_3	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 314 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-1-2	CH_3	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-1-5	CH_3	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-1-8	CH_3	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-2-1	Et	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-2-2	Et	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-2-5	Et	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-2-8	Et	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-3-1	^iPr	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-3-2	^iPr	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-3-3	^iPr	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-3-4	^iPr	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-3-5	^iPr	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-3-6	^iPr	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-3-7	^iPr	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-3-8	^iPr	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 315 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-4-1	^{t}Bu	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-4-2	^{t}Bu	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-4-8	^{t}Bu	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-5-1	Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-5-2	Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-5-5	Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-5-8	Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-6-1	p-Me-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-6-2	p-Me-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-6-8	p-Me-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 316 of 739

Table XIV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-7-1	p-F-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-7-2	p-F-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-7-20	p-F-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-8-1	p-Cl-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-8-8	p-Cl-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-9-1	p-Br-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-9-2	p-Br-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-9-20	p-Br-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 317 of 739

Table XIV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-10-1	p-I-Ph	H	H	H	CH_3	N_3	F	H	OH	H	H
XIV-10-2	p-I-Ph	H	H	CH_3	CH_3	N_3	F	H	OH	H	H
XIV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	N_3	F	H	OH	H	H
XIV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	N_3	F	H	OH	H	H
XIV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	N_3	F	H	OH	H	H
XIV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	N_3	F	H	OH	H	H
XIV-10-8	p-I-Ph	*	H	*	CH_3	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-11-1	CH_3	H	H	H	Et	N_3	F	H	OH	H	H
XIV-11-2	CH_3	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-11-5	CH_3	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-11-8	CH_3	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-12-1	Et	H	H	H	Et	N_3	F	H	OH	H	H
XIV-12-2	Et	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-12-3	Et	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-12-5	Et	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-12-6	Et	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-12-8	Et	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 318 of 739

Table XIV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-13-1	^{i}Pr	H	H	H	Et	N_3	F	H	OH	H	H
XIV-13-2	^{i}Pr	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-13-5	^{i}Pr	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-13-8	^{i}Pr	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-14-1	^{t}Bu	H	H	H	Et	N_3	F	H	OH	H	H
XIV-14-2	^{t}Bu	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-14-5	^{t}Bu	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-14-8	^{t}Bu	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-15-1	Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-15-2	Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-15-5	Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-15-8	Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 319 of 739

Table XIV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-16-1	p-Me-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-16-2	p-Me-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-16-8	p-Me-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-17-1	p-F-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-17-2	p-F-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-17-5	p-F-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-17-8	p-F-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-18-1	p-Cl-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-18-2	p-Cl-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-18-8	p-Cl-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 320 of 739

Table XIV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-19-1	p-Br-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-19-2	p-Br-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-19-8	p-Br-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-20-1	p-I-Ph	H	H	H	Et	N_3	F	H	OH	H	H
XIV-20-2	p-I-Ph	H	H	CH_3	Et	N_3	F	H	OH	H	H
XIV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	N_3	F	H	OH	H	H
XIV-20-5	p-I-Ph	H	H	CH_2Ph	Et	N_3	F	H	OH	H	H
XIV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	N_3	F	H	OH	H	H
XIV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	N_3	F	H	OH	H	H
XIV-20-8	p-I-Ph	*	H	*	Et	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-21-1	CH_3	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-2	CH_3	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-21-8	CH_3	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 321 of 739

Table XIV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-22-1	Et	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-2	Et	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-5	Et	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-22-8	Et	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-23-1	^{i}Pr	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-23-8	^{i}Pr	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-24-1	^{t}Bu	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-24-8	^{t}Bu	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 322 of 739

Table XIV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-25-1	Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-2	Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-25-8	Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-26-1	p-Me-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-26-8	p-Me-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-27-1	p-F-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-27-8	p-F-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 323 of 739

Table XIV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-29-1	p-Br-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-29-8	p-Br-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-30-1	p-I-Ph	H	H	H	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	N_3	F	H	OH	H	H
XIV-30-8	p-I-Ph	*	H	*	^{i}Pr	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 324 of 739

Table XIV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-31-1	CH_3	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-2	CH_3	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-31-8	CH_3	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-32-1	Et	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-2	Et	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-5	Et	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-32-8	Et	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-33-1	^{i}Pr	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-33-8	^{i}Pr	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 325 of 739

Table XIV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-34-1	^{t}Bu	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-34-8	^{t}Bu	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-35-1	Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-2	Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-35-8	Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-36-1	p-Me-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-36-8	p-Me-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 326 of 739

Table XIV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-37-1	p-F-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-37-8	p-F-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-39-1	p-Br-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-39-8	p-Br-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 327 of 739

Table XIV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-40-1	p-I-Ph	H	H	H	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	N_3	F	H	OH	H	H
XIV-40-8	p-I-Ph	*	H	*	^{n}Bu	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-41-1	CH_3	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-41-2	CH_3	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-41-5	CH_3	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-41-8	CH_3	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-42-1	Et	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-42-2	Et	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-42-5	Et	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-42-8	Et	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 328 of 739

Table XIV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-43-1	^{i}Pr	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-43-2	^{i}Pr	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-43-8	^{i}Pr	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-44-1	^{t}Bu	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-44-2	^{t}Bu	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-44-8	^{t}Bu	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-45-1	Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-45-2	Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-45-5	Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-45-8	Ph	*	H	*	Bz	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 329 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-46-1	p-Me-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-46-2	p-Me-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-46-8	p-Me-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-47-1	p-F-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-47-2	p-F-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-47-8	p-F-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-48-1	p-Cl-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-48-2	p-Cl-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 330 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-48-8	p-Cl-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-49-1	p-Br-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-49-2	p-Br-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-49-8	p-Br-Ph	*	H	*	Bz	N_3	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIV-50-1	p-I-Ph	H	H	H	Bz	N_3	F	H	OH	H	H
XIV-50-2	p-I-Ph	H	H	CH_3	Bz	N_3	F	H	OH	H	H
XIV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	N_3	F	H	OH	H	H
XIV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	N_3	F	H	OH	H	H
XIV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	N_3	F	H	OH	H	H
XIV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	N_3	F	H	OH	H	H
XIV-50-8	p-I-Ph	*	H	*	Bz	N_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 331 of 739



XV

Table XV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-1-1	CH_3	H	H	H	CH_3	F	F	H	OH	H	H
XV-1-2	CH_3	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-1-5	CH_3	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-1-8	CH_3	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-2-1	Et	H	H	H	CH_3	F	F	H	OH	H	H
XV-2-2	Et	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-2-5	Et	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-2-8	Et	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 332 of 739

Table XV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-3-1	^{i}Pr	H	H	H	CH_3	F	F	H	OH	H	H
XV-3-2	^{i}Pr	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-3-8	^{i}Pr	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-4-1	^{t}Bu	H	H	H	CH_3	F	F	H	OH	H	H
XV-4-2	^{t}Bu	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-4-8	^{t}Bu	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-5-1	Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-5-2	Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-5-5	Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-5-8	Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 333 of 739

Table XV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-6-1	p-Me-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-6-8	p-Me-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-7-1	p-F-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-7-2	p-F-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-7-20	p-F-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-8-1	p-Cl-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-8-8	p-Cl-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 334 of 739

Table XV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-9-1	p-Br-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-9-20	p-Br-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-10-1	p-I-Ph	H	H	H	CH_3	F	F	H	OH	H	H
XV-10-2	p-I-Ph	H	H	CH_3	CH_3	F	F	H	OH	H	H
XV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	H	OH	H	H
XV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	F	H	OH	H	H
XV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	H	OH	H	H
XV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	H	OH	H	H
XV-10-8	p-I-Ph	*	H	*	CH_3	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-11-1	CH_3	H	H	H	Et	F	F	H	OH	H	H
XV-11-2	CH_3	H	H	CH_3	Et	F	F	H	OH	H	H
XV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-11-5	CH_3	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-11-8	CH_3	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 335 of 739

Table XV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-12-1	Et	H	H	H	Et	F	F	H	OH	H	H
XV-12-2	Et	H	H	CH_3	Et	F	F	H	OH	H	H
XV-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-12-5	Et	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-12-8	Et	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-13-1	^{i}Pr	H	H	H	Et	F	F	H	OH	H	H
XV-13-2	^{i}Pr	H	H	CH_3	Et	F	F	H	OH	H	H
XV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-13-8	^{i}Pr	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-14-1	^{t}Bu	H	H	H	Et	F	F	H	OH	H	H
XV-14-2	^{t}Bu	H	H	CH_3	Et	F	F	H	OH	H	H
XV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-14-8	^{t}Bu	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 336 of 739

Table XV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-15-1	Ph	H	H	H	Et	F	F	H	OH	H	H
XV-15-2	Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-15-5	Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-15-8	Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-16-1	p-Me-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-16-2	p-Me-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-16-8	p-Me-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-17-1	p-F-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-17-2	p-F-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-17-8	p-F-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 337 of 739

Table XV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-18-1	p-Cl-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-18-2	p-Cl-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-18-8	p-Cl-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-19-1	p-Br-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-19-2	p-Br-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-19-8	p-Br-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-20-1	p-I-Ph	H	H	H	Et	F	F	H	OH	H	H
XV-20-2	p-I-Ph	H	H	CH_3	Et	F	F	H	OH	H	H
XV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	H	OH	H	H
XV-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	F	H	OH	H	H
XV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	F	H	OH	H	H
XV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	H	OH	H	H
XV-20-8	p-I-Ph	*	H	*	Et	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 338 of 739

Table XV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-21-1	CH_3	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-21-2	CH_3	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-21-8	CH_3	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-22-1	Et	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-22-2	Et	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-22-8	Et	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-23-1	^{i}Pr	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-23-8	^{i}Pr	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 339 of 739

Table XV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-24-1	^{t}Bu	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-24-8	^{t}Bu	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-25-1	Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-25-2	Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-25-8	Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 340 of 739

Table XV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-27-1	p-F-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-27-8	p-F-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 341 of 739

Table XV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-30-1	p-I-Ph	H	H	H	^{i}Pr	F	F	H	OH	H	H
XV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	F	H	OH	H	H
XV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	H	OH	H	H
XV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	F	H	OH	H	H
XV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	H	OH	H	H
XV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	H	OH	H	H
XV-30-8	p-I-Ph	*	H	*	^{i}Pr	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-31-1	CH_3	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-31-2	CH_3	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-31-8	CH_3	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-32-1	Et	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-32-2	Et	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-32-8	Et	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 342 of 739

Table XV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-33-1	^{i}Pr	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-33-8	^{i}Pr	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-34-1	^{t}Bu	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-34-8	^{t}Bu	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-35-1	Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-35-2	Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-35-8	Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 343 of 739

Table XV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-37-1	p-F-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-37-8	p-F-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 344 of 739

Table XV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-40-1	p-I-Ph	H	H	H	^{n}Bu	F	F	H	OH	H	H
XV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	F	H	OH	H	H
XV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	H	OH	H	H
XV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	F	H	OH	H	H
XV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	H	OH	H	H
XV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	H	OH	H	H
XV-40-8	p-I-Ph	*	H	*	^{n}Bu	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-41-1	CH_3	H	H	H	Bz	F	F	H	OH	H	H
XV-41-2	CH_3	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-41-5	CH_3	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-41-8	CH_3	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 345 of 739

Table XV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-42-1	Et	H	H	H	Bz	F	F	H	OH	H	H
XV-42-2	Et	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-42-5	Et	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-42-8	Et	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-43-1	^{i}Pr	H	H	H	Bz	F	F	H	OH	H	H
XV-43-2	^{i}Pr	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-43-8	^{i}Pr	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-44-1	^{t}Bu	H	H	H	Bz	F	F	H	OH	H	H
XV-44-2	^{t}Bu	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-44-8	^{t}Bu	*	H	*	Bz	F	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 346 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-45-1	Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-45-2	Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-45-5	Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-45-8	Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-46-1	p-Me-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-46-2	p-Me-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-46-8	p-Me-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-47-1	p-F-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-47-2	p-F-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 347 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-47-8	p-F-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-48-1	p-Cl-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-48-8	p-Cl-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-49-1	p-Br-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-49-2	p-Br-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H
XV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-49-8	p-Br-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-50-1	p-I-Ph	H	H	H	Bz	F	F	H	OH	H	H
XV-50-2	p-I-Ph	H	H	CH_3	Bz	F	F	H	OH	H	H
XV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	H	OH	H	H
XV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 348 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	H	OH	H	H
XV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	H	OH	H	H
XV-50-8	p-I-Ph	*	H	*	Bz	F	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XVI

Table XVI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-1-1	CH_3	H	H	H	CH_3	F	F	F	OH	H	H
XVI-1-2	CH_3	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-1-5	CH_3	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-1-8	CH_3	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-2-1	Et	H	H	H	CH_3	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 349 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-2-2	Et	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-2-5	Et	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-2-8	Et	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-3-1	^{i}Pr	H	H	H	CH_3	F	F	F	OH	H	H
XVI-3-2	^{i}Pr	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-3-8	^{i}Pr	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-4-1	^{t}Bu	H	H	H	CH_3	F	F	F	OH	H	H
XVI-4-2	^{t}Bu	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-4-8	^{t}Bu	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-5.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 350 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-5-1	Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-5-2	Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-5-5	Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-5-8	Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-6-1	p-Me-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-6-8	p-Me-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-7-1	p-F-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-7-2	p-F-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-7-20	p-F-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 351 of 739

Table XVI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-8-1	p-Cl-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-8-8	p-Cl-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-9-1	p-Br-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-9-20	p-Br-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-10-1	p-I-Ph	H	H	H	CH_3	F	F	F	OH	H	H
XVI-10-2	p-I-Ph	H	H	CH_3	CH_3	F	F	F	OH	H	H
XVI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	F	F	OH	H	H
XVI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	F	F	OH	H	H
XVI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	F	F	OH	H	H
XVI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	F	F	OH	H	H
XVI-10-8	p-I-Ph	*	H	*	CH_3	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 352 of 739

Table XVI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-11-1	CH_3	H	H	H	Et	F	F	F	OH	H	H
XVI-11-2	CH_3	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-11-5	CH_3	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-11-8	CH_3	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-12-1	Et	H	H	H	Et	F	F	F	OH	H	H
XVI-12-2	Et	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-12-5	Et	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-12-8	Et	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-13-1	^{i}Pr	H	H	H	Et	F	F	F	OH	H	H
XVI-13-2	^{i}Pr	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-13-8	^{i}Pr	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 353 of 739

Table XVI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-14-1	^{t}Bu	H	H	H	Et	F	F	F	OH	H	H
XVI-14-2	^{t}Bu	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-14-8	^{t}Bu	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-15-1	Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-15-2	Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-15-5	Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-15-8	Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-16-1	p-Me-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-16-2	p-Me-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-16-8	p-Me-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 354 of 739

Table XVI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-17-1	p-F-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-17-2	p-F-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-17-8	p-F-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-18-1	p-Cl-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-18-2	p-Cl-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-18-8	p-Cl-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-19-1	p-Br-Ph	H	H	H	Et	F	F	F	OH	H	H
XVI-19-2	p-Br-Ph	H	H	CH_3	Et	F	F	F	OH	H	H
XVI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H	H
XVI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H	H
XVI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H	H
XVI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H	H
XVI-19-8	p-Br-Ph	*	H	*	Et	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 355 of 739

Table XVI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XVI-20-1	p-I-Ph	H	H	H	Et	F	F	F	OH	H
XVI-20-2	p-I-Ph	H	H	CH_3	Et	F	F	F	OH	H
XVI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	F	F	OH	H
XVI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	F	F	OH	H
XVI-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	F	F	OH	H
XVI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	F	F	OH	H
XVI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	F	F	OH	H
XVI-20-8	p-I-Ph	*	H	*	Et	F	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-21-1	CH_3	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-21-2	CH_3	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-21-8	CH_3	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-22-1	Et	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-22-2	Et	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-22-8	Et	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 356 of 739

Table XVI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-23-1	^{i}Pr	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-23-8	^{i}Pr	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-24-1	^{t}Bu	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-24-8	^{t}Bu	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-25-1	Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-25-2	Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-25-8	Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 357 of 739

Table XVI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-27-1	p-F-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-27-8	p-F-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 358 of 739

Table XVI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-30-1	p-I-Ph	H	H	H	^{i}Pr	F	F	F	OH	H	H
XVI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	F	F	OH	H	H
XVI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	F	F	OH	H	H
XVI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	F	F	OH	H	H
XVI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	F	F	OH	H	H
XVI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	F	F	OH	H	H
XVI-30-8	p-I-Ph	*	H	*	^{i}Pr	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-31-1	CH_3	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-31-2	CH_3	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-31-8	CH_3	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 359 of 739

Table XVI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-32-1	Et	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-32-2	Et	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-32-8	Et	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-33-1	^{i}Pr	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-33-8	^{i}Pr	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-34-1	^{t}Bu	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-34-8	^{t}Bu	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 360 of 739

Table XVI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-35-1	Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-35-2	Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-35-8	Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-37-1	p-F-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-37-8	p-F-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 361 of 739

Table XVI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-40-1	p-I-Ph	H	H	H	^{n}Bu	F	F	F	OH	H	H
XVI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	F	F	OH	H	H
XVI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	F	F	OH	H	H
XVI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	F	F	OH	H	H
XVI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	F	F	OH	H	H
XVI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	F	F	OH	H	H
XVI-40-8	p-I-Ph	*	H	*	^{n}Bu	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 362 of 739

Table XVI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-41-1	CH_3	H	H	H	Bz	F	F	F	OH	H	H
XVI-41-2	CH_3	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-41-5	CH_3	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-41-8	CH_3	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-42-1	Et	H	H	H	Bz	F	F	F	OH	H	H
XVI-42-2	Et	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-42-5	Et	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-42-8	Et	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-43-1	^{i}Pr	H	H	H	Bz	F	F	F	OH	H	H
XVI-43-2	^{i}Pr	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-43-8	^{i}Pr	*	H	*	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 363 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVI-44-1	^{t}Bu	H	H	H	Bz	F	F	F	OH	H	H
XVI-44-2	^{t}Bu	H	H	CH_3	Bz	F	F	F	OH	H	H
XVI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVI-44-8	^{t}Bu	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-45-1	Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-45-2	Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-45-5	Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-45-8	Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-1	p-Me-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-46-2	p-Me-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 364 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-8	p-Me-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-47-1	p-F-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-47-2	p-F-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-47-8	p-F-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-1	p-Cl-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-48-8	p-Cl-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-1	p-Br-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-49-2	p-Br-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 365 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-49-8	p-Br-Ph	*	H	*	Bz	F	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-50-1	p-I-Ph	H	H	H	Bz	F	F	F	OH	H	H
XVII-50-2	p-I-Ph	H	H	CH_3	Bz	F	F	F	OH	H	H
XVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	F	F	OH	H	H
XVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	F	F	OH	H	H
XVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	F	F	OH	H	H
XVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	F	F	OH	H	H
XVII-50-8	p-I-Ph	*	H	*	Bz	F	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XVII

Table XVII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-1-1	CH_3	H	H	H	CH_3	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 366 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-1-2	CH_3	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-1-5	CH_3	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-1-8	CH_3	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-2-1	Et	H	H	H	CH_3	F	H	F	OH	H	H
XVII-2-2	Et	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-2-5	Et	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-2-8	Et	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-3-1	^{i}Pr	H	H	H	CH_3	F	H	F	OH	H	H
XVII-3-2	^{i}Pr	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-3-8	^{i}Pr	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 367 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-4-1	^{t}Bu	H	H	H	CH_3	F	H	F	OH	H	H
XVII-4-2	^{t}Bu	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-4-8	^{t}Bu	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-5-1	Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-5-2	Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-5-5	Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-5-8	Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-6-1	p-Me-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-6-2	p-Me-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-6-8	p-Me-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 368 of 739

Table XVII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-7-1	p-F-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-7-2	p-F-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-7-20	p-F-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-8-1	p-Cl-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-8-8	p-Cl-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-9-1	p-Br-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-9-2	p-Br-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-9-20	p-Br-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 369 of 739

Table XVII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-10-1	p-I-Ph	H	H	H	CH_3	F	H	F	OH	H	H
XVII-10-2	p-I-Ph	H	H	CH_3	CH_3	F	H	F	OH	H	H
XVII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	F	H	F	OH	H	H
XVII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	F	H	F	OH	H	H
XVII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	F	H	F	OH	H	H
XVII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	F	H	F	OH	H	H
XVII-10-8	p-I-Ph	*	H	*	CH_3	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-11-1	CH_3	H	H	H	Et	F	H	F	OH	H	H
XVII-11-2	CH_3	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-11-5	CH_3	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-11-8	CH_3	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-12-1	Et	H	H	H	Et	F	H	F	OH	H	H
XVII-12-2	Et	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-12-3	Et	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-12-5	Et	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-12-6	Et	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-12-8	Et	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 370 of 739

Table XVII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-13-1	^{i}Pr	H	H	H	Et	F	H	F	OH	H	H
XVII-13-2	^{i}Pr	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-13-5	^{i}Pr	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-13-8	^{i}Pr	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-14-1	^{t}Bu	H	H	H	Et	F	H	F	OH	H	H
XVII-14-2	^{t}Bu	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-14-5	^{t}Bu	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-14-8	^{t}Bu	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-15-1	Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-15-2	Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-15-5	Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-15-8	Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 371 of 739

Table XVII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-16-1	p-Me-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-16-2	p-Me-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-16-8	p-Me-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-17-1	p-F-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-17-2	p-F-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-17-5	p-F-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-17-8	p-F-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-18-1	p-Cl-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-18-2	p-Cl-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-18-8	p-Cl-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 372 of 739

Table XVII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-19-1	p-Br-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-19-2	p-Br-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-19-8	p-Br-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-20-1	p-I-Ph	H	H	H	Et	F	H	F	OH	H	H
XVII-20-2	p-I-Ph	H	H	CH_3	Et	F	H	F	OH	H	H
XVII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	F	H	F	OH	H	H
XVII-20-5	p-I-Ph	H	H	CH_2Ph	Et	F	H	F	OH	H	H
XVII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	F	H	F	OH	H	H
XVII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	F	H	F	OH	H	H
XVII-20-8	p-I-Ph	*	H	*	Et	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-21-1	CH_3	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-21-2	CH_3	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-21-8	CH_3	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 373 of 739

Table XVII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-22-1	Et	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-22-2	Et	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-22-5	Et	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-22-8	Et	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-23-1	^{i}Pr	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-23-8	^{i}Pr	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-24-1	^{t}Bu	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-24-8	^{t}Bu	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 374 of 739

Table XVII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-25-1	Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-25-2	Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-25-8	Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-26-1	p-Me-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-26-8	p-Me-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-27-1	p-F-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-27-8	p-F-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 375 of 739

Table XVII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-29-1	p-Br-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-29-8	p-Br-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-30-1	p-I-Ph	H	H	H	^{i}Pr	F	H	F	OH	H	H
XVII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	F	H	F	OH	H	H
XVII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	F	H	F	OH	H	H
XVII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	F	H	F	OH	H	H
XVII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	F	H	F	OH	H	H
XVII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	F	H	F	OH	H	H
XVII-30-8	p-I-Ph	*	H	*	^{i}Pr	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 376 of 739

Table XVII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-31-1	CH_3	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-31-2	CH_3	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-31-8	CH_3	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-32-1	Et	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-32-2	Et	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-32-5	Et	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-32-8	Et	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-33-1	^{i}Pr	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-33-8	^{i}Pr	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 377 of 739

Table XVII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-34-1	^{t}Bu	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-34-8	^{t}Bu	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-35-1	Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-35-2	Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-35-8	Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-36-1	p-Me-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-36-8	p-Me-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 378 of 739

Table XVII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-37-1	p-F-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-37-8	p-F-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-39-1	p-Br-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-39-8	p-Br-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 379 of 739

Table XVII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-40-1	p-I-Ph	H	H	H	^{n}Bu	F	H	F	OH	H	H
XVII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	F	H	F	OH	H	H
XVII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	F	H	F	OH	H	H
XVII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	F	H	F	OH	H	H
XVII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	F	H	F	OH	H	H
XVII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	F	H	F	OH	H	H
XVII-40-8	p-I-Ph	*	H	*	^{n}Bu	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-41-1	CH_3	H	H	H	Bz	F	H	F	OH	H	H
XVII-41-2	CH_3	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-41-5	CH_3	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-41-8	CH_3	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-42-1	Et	H	H	H	Bz	F	H	F	OH	H	H
XVII-42-2	Et	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-42-5	Et	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-42-8	Et	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 380 of 739

Table XVII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-43-1	^{i}Pr	H	H	H	Bz	F	H	F	OH	H	H
XVII-43-2	^{i}Pr	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-43-8	^{i}Pr	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-44-1	^{t}Bu	H	H	H	Bz	F	H	F	OH	H	H
XVII-44-2	^{t}Bu	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-44-8	^{t}Bu	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-45-1	Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-45-2	Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-45-5	Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-45-8	Ph	*	H	*	Bz	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 381 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-46-1	p-Me-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-46-2	p-Me-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-46-8	p-Me-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-47-1	p-F-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-47-2	p-F-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-47-8	p-F-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-1	p-Cl-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 382 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-48-8	p-Cl-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-49-1	p-Br-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-49-2	p-Br-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-49-8	p-Br-Ph	*	H	*	Bz	F	H	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVII-50-1	p-I-Ph	H	H	H	Bz	F	H	F	OH	H	H
XVII-50-2	p-I-Ph	H	H	CH_3	Bz	F	H	F	OH	H	H
XVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	F	H	F	OH	H	H
XVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	F	H	F	OH	H	H
XVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	F	H	F	OH	H	H
XVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	F	H	F	OH	H	H
XVII-50-8	p-I-Ph	*	H	*	Bz	F	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 383 of 739



XVIII

Table XVIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-1-1	CH_3	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-1-8	CH_3	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-2-1	Et	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-2	Et	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-2-8	Et	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 384 of 739

Table XVIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-5-1	Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-2	Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-5-8	Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 385 of 739

Table XVIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 386 of 739

Table XVIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	H	OH	H	H
XVIII-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-11-1	CH_3	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-11-2	CH_3	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-11-8	CH_3	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 387 of 739

Table XVIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-12-1	Et	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-12-2	Et	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-12-5	Et	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-12-8	Et	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-13-1	^{i}Pr	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-13-8	^{i}Pr	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-14-1	^{t}Bu	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-14-8	^{t}Bu	*	H	*	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 388 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-15-1	Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-15-2	Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-15-8	Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-16-1	p-Me-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-16-8	p-Me-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-17-1	p-F-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 389 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-17-8	p-F-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-19-1	p-Br-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H
XVIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-19-8	p-Br-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-20-1	p-I-Ph	H	H	H	Et	OCH_3	F	H	OH	H	H
XVIII-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	F	H	OH	H	H
XVIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	H	OH	H	H
XVIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 390 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	H	OH	H	H
XVIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	H	OH	H	H
XVIII-20-8	p-I-Ph	*	H	*	Et	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-22-1	Et	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-22-8	Et	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 391 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-25-1	Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-25-8	Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 392 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-29.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 393 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	H	OH	H	H
XVIII-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 394 of 739

Table XVIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-32-1	Et	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-32-8	Et	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 395 of 739

Table XVIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-35-1	Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-35-8	Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 396 of 739

Table XVIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	H	OH	H	H
XVIII-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 397 of 739

Table XVIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-41-1	CH_3	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-41-2	CH_3	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-41-8	CH_3	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-42-1	Et	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-42-2	Et	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-42-8	Et	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-43-1	^{i}Pr	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-43-8	^{i}Pr	*	H	*	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 398 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-44-1	^{t}Bu	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-44-8	^{t}Bu	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-45-1	Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-45-2	Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-45-8	Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 399 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-47-1	p-F-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-47-8	p-F-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 400 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XVIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XVIII-50-1	p-I-Ph	H	H	H	Bz	OCH_3	F	H	OH	H	H
XVIII-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	F	H	OH	H	H
XVIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	F	H	OH	H	H
XVIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	H	OH	H	H
XVIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	H	OH	H	H
XVIII-50-8	p-I-Ph	*	H	*	Bz	OCH_3	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XIX

Table XIX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-1-1	CH_3	H	H	H	CH_3	OCH_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 401 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-1-8	CH_3	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-2-1	Et	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-2-2	Et	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-2-8	Et	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-4.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 402 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-5-1	Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-5-2	Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-5-8	Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 403 of 739

Table XIX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 404 of 739

Table XIX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	F	F	OH	H	H
XIX-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	F	F	OH	H	H
XIX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	F	F	OH	H	H
XIX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	F	F	OH	H	H
XIX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	F	F	OH	H	H
XIX-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-11-1	CH_3	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-11-2	CH_3	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-11-8	CH_3	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-12-1	Et	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-12-2	Et	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-12-5	Et	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-12-8	Et	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 405 of 739

Table XIX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-13-1	^{i}Pr	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-13-8	^{i}Pr	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-14-1	^{t}Bu	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-14-8	^{t}Bu	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-15-1	Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-15-2	Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-15-8	Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 406 of 739

Table XIX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-16-1	p-Me-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-16-8	p-Me-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-17-1	p-F-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-17-8	p-F-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 407 of 739

Table XIX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-19-1	p-Br-Ph	H	H	H	Et	OCH_3	F	F	OH	H	H
XIX-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H	H
XIX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H	H
XIX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H	H
XIX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H	H
XIX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H	H
XIX-19-8	p-Br-Ph	*	H	*	Et	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7
XIX-20-1	p-I-Ph	H	H	H	Et	OCH_3	F	F	OH	H
XIX-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	F	F	OH	H
XIX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	F	F	OH	H
XIX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	F	F	OH	H
XIX-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	F	F	OH	H
XIX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	F	F	OH	H
XIX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	F	F	OH	H
XIX-20-8	p-I-Ph	*	H	*	Et	OCH_3	F	F	OH	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 408 of 739

Table XIX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-22-1	Et	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-22-8	Et	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 409 of 739

Table XIX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-25-1	Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-25-8	Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 410 of 739

Table XIX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	F	F	OH	H	H
XIX-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 411 of 739

Table XIX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-32-1	Et	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-32-8	Et	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 412 of 739

Table XIX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-35-1	Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-35-8	Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 413 of 739

Table XIX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 414 of 739

Table XIX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	F	F	OH	H	H
XIX-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-41-1	CH_3	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-41-2	CH_3	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-41-8	CH_3	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-42-1	Et	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-42-2	Et	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-42-8	Et	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 415 of 739

Table XIX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-43-1	^{i}Pr	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-43-8	^{i}Pr	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-44-1	^{t}Bu	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-44-8	^{t}Bu	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-45-1	Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-45-2	Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-45-8	Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 416 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-47-1	p-F-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-47-8	p-F-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 417 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XIX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XIX-50-1	p-I-Ph	H	H	H	Bz	OCH_3	F	F	OH	H	H
XIX-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	F	F	OH	H	H
XIX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	F	F	OH	H	H
XIX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	F	F	OH	H	H
XIX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	F	F	OH	H	H
XIX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	F	F	OH	H	H
XIX-50-8	p-I-Ph	*	H	*	Bz	OCH_3	F	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 418 of 739



XX

Table XX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-1-1	CH_3	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-1-2	CH_3	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-1-5	CH_3	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-1-8	CH_3	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-2-1	Et	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-2-2	Et	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-2-5	Et	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-2-8	Et	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 419 of 739

Table XX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-3-1	^{i}Pr	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-3-2	^{i}Pr	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-3-8	^{i}Pr	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-4-1	^{t}Bu	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-4-2	^{t}Bu	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-4-8	^{t}Bu	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-5-1	Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-5-2	Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-5-5	Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-5-8	Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 420 of 739

Table XX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-6-1	p-Me-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-6-2	p-Me-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-6-8	p-Me-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-7-1	p-F-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-7-2	p-F-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-7-20	p-F-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-8-1	p-Cl-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-8-8	p-Cl-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 421 of 739

Table XX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-9-1	p-Br-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-9-2	p-Br-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-9-20	p-Br-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-10-1	p-I-Ph	H	H	H	CH_3	OCH_3	H	F	OH	H	H
XX-10-2	p-I-Ph	H	H	CH_3	CH_3	OCH_3	H	F	OH	H	H
XX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	OCH_3	H	F	OH	H	H
XX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	OCH_3	H	F	OH	H	H
XX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	OCH_3	H	F	OH	H	H
XX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	OCH_3	H	F	OH	H	H
XX-10-8	p-I-Ph	*	H	*	CH_3	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-11-1	CH_3	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-11-2	CH_3	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-11-5	CH_3	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-11-8	CH_3	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 422 of 739

Table XX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-12-1	Et	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-12-2	Et	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-12-3	Et	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-12-5	Et	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-12-6	Et	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-12-8	Et	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-13-1	^{i}Pr	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-13-2	^{i}Pr	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-13-5	^{i}Pr	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-13-8	^{i}Pr	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-14-1	^{t}Bu	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-14-2	^{t}Bu	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-14-5	^{t}Bu	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-14-8	^{t}Bu	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 423 of 739

Table XX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-15-1	Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-15-2	Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-15-5	Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-15-8	Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-16-1	p-Me-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-16-2	p-Me-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-16-8	p-Me-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-17-1	p-F-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-17-2	p-F-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-17-5	p-F-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-17-8	p-F-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 424 of 739

Table XX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-18-1	p-Cl-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-18-2	p-Cl-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-18-8	p-Cl-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-19-1	p-Br-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-19-2	p-Br-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-19-8	p-Br-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-20-1	p-I-Ph	H	H	H	Et	OCH_3	H	F	OH	H	H
XX-20-2	p-I-Ph	H	H	CH_3	Et	OCH_3	H	F	OH	H	H
XX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	OCH_3	H	F	OH	H	H
XX-20-5	p-I-Ph	H	H	CH_2Ph	Et	OCH_3	H	F	OH	H	H
XX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	OCH_3	H	F	OH	H	H
XX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	OCH_3	H	F	OH	H	H
XX-20-8	p-I-Ph	*	H	*	Et	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 425 of 739

Table XX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-21-1	CH_3	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-2	CH_3	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-21-8	CH_3	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-22-1	Et	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-2	Et	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-5	Et	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-22-8	Et	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-23-1	^{i}Pr	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-23-8	^{i}Pr	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 426 of 739

Table XX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-24-1	^{t}Bu	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-24-8	^{t}Bu	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-25-1	Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-2	Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-25-8	Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-26-1	p-Me-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-26-8	p-Me-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 427 of 739

Table XX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-27-1	p-F-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-27-8	p-F-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-29-1	p-Br-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-29-8	p-Br-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 428 of 739

Table XX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-30-1	p-I-Ph	H	H	H	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	OCH_3	H	F	OH	H	H
XX-30-8	p-I-Ph	*	H	*	^{i}Pr	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-31-1	CH_3	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-2	CH_3	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-31-8	CH_3	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-32-1	Et	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-2	Et	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-5	Et	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-32-8	Et	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 429 of 739

Table XX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-33-1	^{i}Pr	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-33-8	^{i}Pr	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-34-1	^{t}Bu	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-34-8	^{t}Bu	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-35-1	Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-2	Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-35-8	Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 430 of 739

Table XX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-36-1	p-Me-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-36-8	p-Me-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-37-1	p-F-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-37-8	p-F-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 431 of 739

Table XX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-39-1	p-Br-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-39-8	p-Br-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-40-1	p-I-Ph	H	H	H	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	OCH_3	H	F	OH	H	H
XX-40-8	p-I-Ph	*	H	*	^{n}Bu	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-41-1	CH_3	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-41-2	CH_3	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-41-5	CH_3	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-41-8	CH_3	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 432 of 739

Table XX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-42-1	Et	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-42-2	Et	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-42-5	Et	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-42-8	Et	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-43-1	^{i}Pr	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-43-2	^{i}Pr	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-43-8	^{i}Pr	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-44-1	^{t}Bu	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-44-2	^{t}Bu	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-44-8	^{t}Bu	*	H	*	Bz	OCH_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 433 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-45-1	Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-45-2	Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-45-5	Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-45-8	Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-46-1	p-Me-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-46-2	p-Me-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-46-8	p-Me-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-47-1	p-F-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-47-2	p-F-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 434 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-47-8	p-F-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-48-1	p-Cl-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-48-2	p-Cl-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-48-8	p-Cl-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-49-1	p-Br-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-49-2	p-Br-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H
XX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-49-8	p-Br-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-50-1	p-I-Ph	H	H	H	Bz	OCH_3	H	F	OH	H	H
XX-50-2	p-I-Ph	H	H	CH_3	Bz	OCH_3	H	F	OH	H	H
XX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	OCH_3	H	F	OH	H	H
XX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	OCH_3	H	F	OH	H	H

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 435 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
XX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	OCH_3	H	F	OH	H	H
XX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	OCH_3	H	F	OH	H	H
XX-50-8	p-I-Ph	*	H	*	Bz	OCH_3	H	F	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXI

Table XXI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXI-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXI-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 436 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH
XXI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 437 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-8.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 438 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXI-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 439 of 739

Table XXI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXI-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXI-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXI-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 440 of 739

Table XXI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXI-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXI-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 441 of 739

Table XXI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 442 of 739

Table XXI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXI-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXI-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 443 of 739

Table XXI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 444 of 739

Table XXI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 445 of 739

Table XXI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 446 of 739

Table XXI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 447 of 739

Table XXI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 448 of 739

Table XXI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 449 of 739

Table XXI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXI-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXI-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXI-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 450 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXI-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 451 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 452 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXI-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXI-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXI-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXII

Table XXII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXII-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH
XXII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 453 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXII-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH
XXII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH
XXII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 454 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXII-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-7.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 455 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 456 of 739

Table XXII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXII-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXII-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-12-1	Et	H	H	H	Et	H	F	H	OH
XXII-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 457 of 739

Table XXII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH
XXII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-15-1	Ph	H	H	H	Et	H	F	H	OH
XXII-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 458 of 739

Table XXII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 459 of 739

Table XXII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXII-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 460 of 739

Table XXII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 461 of 739

Table XXII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 462 of 739

Table XXII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 463 of 739

Table XXII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-31-1	CH_3	H	H	H	^nBu	H	F	H	OH
XXII-31-2	CH_3	H	H	CH_3	^nBu	H	F	H	OH
XXII-31-3	CH_3	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-31-5	CH_3	H	H	CH_2Ph	^nBu	H	F	H	OH
XXII-31-6	CH_3	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXII-31-8	CH_3	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-32-1	Et	H	H	H	^nBu	H	F	H	OH
XXII-32-2	Et	H	H	CH_3	^nBu	H	F	H	OH
XXII-32-3	Et	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-32-5	Et	H	H	CH_2Ph	^nBu	H	F	H	OH
XXII-32-6	Et	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXII-32-8	Et	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-33-1	^iPr	H	H	H	^nBu	H	F	H	OH
XXII-33-2	^iPr	H	H	CH_3	^nBu	H	F	H	OH
XXII-33-3	^iPr	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-33-4	^iPr	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXII-33-5	^iPr	H	H	CH_2Ph	^nBu	H	F	H	OH
XXII-33-6	^iPr	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXII-33-7	^iPr	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXII-33-8	^iPr	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 464 of 739

Table XXII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 465 of 739

Table XXII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 466 of 739

Table XXII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXII-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-42-1	Et	H	H	H	Bz	H	F	H	OH
XXII-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 467 of 739

Table XXII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXII-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-45-8	Ph	*	H	*	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 468 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 469 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXII-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXII-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 470 of 739



XXIII

Table XXIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXIII-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXIII-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-3.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 471 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXIII-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 472 of 739

Table XXIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 473 of 739

Table XXIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXIII-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXIII-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 474 of 739

Table XXIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-12-1	Et	H	H	H	Et	H	F	F	OH
XXIII-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXIII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXIII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 475 of 739

Table XXIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-15-1	Ph	H	H	H	Et	H	F	F	OH
XXIII-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXIII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 476 of 739

Table XXIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXIII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXIII-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 477 of 739

Table XXIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXIII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 478 of 739

Table XXIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 479 of 739

Table XXIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 480 of 739

Table XXIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXIII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 481 of 739

Table XXIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 482 of 739

Table XXIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 483 of 739

Table XXIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXIII-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 484 of 739

Table XXIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-42-1	Et	H	H	H	Bz	H	F	F	OH
XXIII-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 485 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXIII-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 486 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XXIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 487 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXIII-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXIV

Table XXIV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXIV-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXIV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXIV-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXIV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 488 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXIV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXIV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXIV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXIV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXIV-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 489 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 490 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXIV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXIV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXIV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXIV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXIV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXIV-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 491 of 739

Table XXIV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXIV-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXIV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-12-1	Et	H	H	H	Et	H	H	F	OH
XXIV-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXIV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXIV-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXIV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 492 of 739

Table XXIV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXIV-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXIV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-15-1	Ph	H	H	H	Et	H	H	F	OH
XXIV-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXIV-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 493 of 739

Table XXIV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXIV-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXIV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXIV-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 494 of 739

Table XXIV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXIV-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXIV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXIV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXIV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXIV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXIV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXIV-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXIV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXIV-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 495 of 739

Table XXIV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXIV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXIV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 496 of 739

Table XXIV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 497 of 739

Table XXIV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXIV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXIV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXIV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXIV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXIV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXIV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXIV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 498 of 739

Table XXIV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXIV-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXIV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXIV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 499 of 739

Table XXIV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 500 of 739

Table XXIV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXIV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXIV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXIV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXIV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXIV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXIV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 501 of 739

Table XXIV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXIV-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXIV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-42-1	Et	H	H	H	Bz	H	H	F	OH
XXIV-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXIV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXIV-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXIV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 502 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXIV-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXIV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXIV-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXIV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 503 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXIV-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-48-1	p-Cl-Ph	H	H	H					OH
XXIV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXIV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 504 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIV-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXIV-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXIV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXIV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXIV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXIV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXIV-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXV

Table XXV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXV-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 505 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXV-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 506 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-7.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 507 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 508 of 739

Table XXV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXV-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXV-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXV-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 509 of 739

Table XXV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXV-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXV-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXV-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 510 of 739

Table XXV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 511 of 739

Table XXV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXV-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXV-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 512 of 739

Table XXV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 513 of 739

Table XXV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 514 of 739

Table XXV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 515 of 739

Table XXV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-31-1	CH_3	H	H	H	^nBu	H	CH_3	F	OH
XXV-31-2	CH_3	H	H	CH_3	^nBu	H	CH_3	F	OH
XXV-31-3	CH_3	H	H	$CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-31-5	CH_3	H	H	CH_2Ph	^nBu	H	CH_3	F	OH
XXV-31-6	CH_3	H	H	CH_2-indol-3-yl	^nBu	H	CH_3	F	OH
XXV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^nBu	H	CH_3	F	OH
XXV-31-8	CH_3	*	H	*	^nBu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-32-1	Et	H	H	H	^nBu	H	CH_3	F	OH
XXV-32-2	Et	H	H	CH_3	^nBu	H	CH_3	F	OH
XXV-32-3	Et	H	H	$CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-32-5	Et	H	H	CH_2Ph	^nBu	H	CH_3	F	OH
XXV-32-6	Et	H	H	CH_2-indol-3-yl	^nBu	H	CH_3	F	OH
XXV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^nBu	H	CH_3	F	OH
XXV-32-8	Et	*	H	*	^nBu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-33-1	^iPr	H	H	H	^nBu	H	CH_3	F	OH
XXV-33-2	^iPr	H	H	CH_3	^nBu	H	CH_3	F	OH
XXV-33-3	^iPr	H	H	$CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-33-4	^iPr	H	H	$CH_2CH(CH_3)_2$	^nBu	H	CH_3	F	OH
XXV-33-5	^iPr	H	H	CH_2Ph	^nBu	H	CH_3	F	OH
XXV-33-6	^iPr	H	H	CH_2-indol-3-yl	^nBu	H	CH_3	F	OH
XXV-33-7	^iPr	H	H	$CH_2CH_2SCH_3$	^nBu	H	CH_3	F	OH
XXV-33-8	^iPr	*	H	*	^nBu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 516 of 739

Table XXV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 517 of 739

Table XXV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 518 of 739

Table XXV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXV-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXV-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 519 of 739

Table XXV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXV-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXV-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 520 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 521 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXV-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXV-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXV-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 522 of 739



XXVI

Table XXVI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXVI-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH
XXVI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXVI-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXVI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-3.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 523 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH
XXVI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH
XXVI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH
XXVI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXVI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXVI-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 524 of 739

Table XXVI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 525 of 739

Table XXVI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXVI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXVI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXVI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXVI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXVI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXVI-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXVI-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXVI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 526 of 739

Table XXVI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-12-1	Et	H	H	H	Et	H	F	H	OH
XXVI-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXVI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXVI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXVI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH
XXVI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXVI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 527 of 739

Table XXVI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-15-1	Ph	H	H	H	Et	H	F	H	OH
XXVI-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXVI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXVI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 528 of 739

Table XXVI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXVI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXVI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXVI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXVI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXVI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXVI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXVI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXVI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXVI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 529 of 739

Table XXVI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXVI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXVI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXVI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 530 of 739

Table XXVI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXVI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 531 of 739

Table XXVI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 532 of 739

Table XXVI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXVI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXVI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXVI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXVI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXVI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXVI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH
XXVI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH
XXVI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 533 of 739

Table XXVI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH
XXVI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXVI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 534 of 739

Table XXVI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 535 of 739

Table XXVI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXVI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXVI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXVI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXVI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXVI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXVI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXVI-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXVI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 536 of 739

Table XXVI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-42-1	Et	H	H	H	Bz	H	F	H	OH
XXVI-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXVI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXVI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXVI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXVI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXVI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 537 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXVI-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-45-8	Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXVI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXVI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 538 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXVI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXVI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXVI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XXVI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXVI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXVI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXVI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 539 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXVI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXVI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXVII

Table XXVII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXVII-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXVII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXVII-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXVII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 540 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXVII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXVII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXVII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXVII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXVII-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 541 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 542 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXVII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXVII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXVII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXVII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXVII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXVII-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 543 of 739

Table XXVII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXVII-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXVII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-12-1	Et	H	H	H	Et	H	F	F	OH
XXVII-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXVII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXVII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXVII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 544 of 739

Table XXVII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXVII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXVII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-15-1	Ph	H	H	H	Et	H	F	F	OH
XXVII-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXVII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 545 of 739

Table XXVII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXVII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXVII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXVII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 546 of 739

Table XXVII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXVII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXVII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXVII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXVII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXVII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXVII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXVII-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXVII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXVII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 547 of 739

Table XXVII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXVII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXVII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 548 of 739

Table XXVII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 549 of 739

Table XXVII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXVII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXVII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXVII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXVII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXVII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXVII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXVII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 550 of 739

Table XXVII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXVII-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXVII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXVII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 551 of 739

Table XXVII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 552 of 739

Table XXVII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXVII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXVII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXVII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXVII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXVII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXVII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 553 of 739

Table XXVII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXVII-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXVII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-42-1	Et	H	H	H	Bz	H	F	F	OH
XXVII-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXVII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXVII-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXVII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 554 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXVII-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXVII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXVII-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXVII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 555 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXVII-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXVII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXVII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 556 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVII-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXVII-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXVII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXVII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXVII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXVII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXVII-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXVIII

Table XXVIII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXVIII-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 557 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXVIII-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXVIII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXVIII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 558 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 559 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 560 of 739

Table XXVIII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXVIII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXVIII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXVIII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXVIII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXVIII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXVIII-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXVIII-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXVIII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-12-1	Et	H	H	H	Et	H	H	F	OH
XXVIII-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXVIII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 561 of 739

Table XXVIII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXVIII-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXVIII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXVIII-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXVIII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXVIII-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 562 of 739

Table XXVIII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXVIII-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXVIII-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXVIII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 563 of 739

Table XXVIII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXVIII-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXVIII-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXVIII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXVIII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXVIII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXVIII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXVIII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 564 of 739

Table XXVIII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 565 of 739

Table XXVIII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 566 of 739

Table XXVIII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXVIII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXVIII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXVIII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXVIII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXVIII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXVIII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 567 of 739

Table XXVIII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 568 of 739

Table XXVIII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 569 of 739

Table XXVIII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 570 of 739

Table XXVIII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXVIII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXVIII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXVIII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXVIII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXVIII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXVIII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXVIII-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXVIII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXVIII-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXVIII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 571 of 739

Table XXVIII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXVIII-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXVIII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXVIII-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXVIII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXVIII-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-45-8	Ph	*	H	*	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 572 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 573 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXVIII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXVIII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXVIII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXVIII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXVIII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXVIII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXVIII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 574 of 739



XXIX

Table XXIX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH
XXIX-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH
XXIX-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-3.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 575 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH
XXIX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH
XXIX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 576 of 739

Table XXIX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 577 of 739

Table XXIX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH
XXIX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH
XXIX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH
XXIX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH
XXIX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH
XXIX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH
XXIX-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH
XXIX-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 578 of 739

Table XXIX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-12-1	Et	H	H	H	Et	H	CH_3	F	OH
XXIX-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-12-8	Et	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH
XXIX-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH
XXIX-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-14-7	^{t}Bu	H	H	CH_2CH_2SCH	Et	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 579 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-15-1	Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-15-8	Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 580 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH
XXIX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH
XXIX-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 581 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH
XXIX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH
XXIX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH
XXIX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH
XXIX-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 582 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 583 of 739

Table XXIX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 584 of 739

Table XXIX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH
XXIX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH
XXIX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH
XXIX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH
XXIX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH
XXIX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH
XXIX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 585 of 739

Table XXIX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 586 of 739

Table XXIX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 587 of 739

Table XXIX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH
XXIX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH
XXIX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH
XXIX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH
XXIX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH
XXIX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH
XXIX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 588 of 739

Table XXIX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH
XXIX-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-42-1	Et	H	H	H	Bz	H	CH_3	F	OH
XXIX-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-42-8	Et	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH
XXIX-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 589 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH
XXIX-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 590 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 591 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXIX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXIX-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH
XXIX-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH
XXIX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH
XXIX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH
XXIX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH
XXIX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH
XXIX-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

5



XXX

Table XXX-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-1-1	CH_3	H	H	H	CH_3	H	F	H	OH
XXX-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 592 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-1-8	CH_3	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-2-1	Et	H	H	H	CH_3	H	F	H	OH
XXX-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH
XXX-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-2-8	Et	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH
XXX-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH
XXX-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 593 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH
XXX-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH
XXX-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-5-1	Ph	H	H	H	CH_3	H	F	H	OH
XXX-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-5-8	Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH
XXX-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 594 of 739

Table XXX-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH
XXX-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH
XXX-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH
XXX-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 595 of 739

Table XXX-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH
XXX-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH
XXX-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH
XXX-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH
XXX-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH
XXX-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH
XXX-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-11-1	CH_3	H	H	H	Et	H	F	H	OH
XXX-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH
XXX-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH
XXX-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-11-8	CH_3	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-12-1	Et	H	H	H	Et	H	F	H	OH
XXX-12-2	Et	H	H	CH_3	Et	H	F	H	OH
XXX-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH
XXX-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-12-8	Et	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 596 of 739

Table XXX-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH
XXX-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH
XXX-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH
XXX-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH
XXX-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH
XXX-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH
XXX-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-15-1	Ph	H	H	H	Et	H	F	H	OH
XXX-15-2	Ph	H	H	CH_3	Et	H	F	H	OH
XXX-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-15-8	Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 597 of 739

Table XXX-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXX-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXX-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXX-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 598 of 739

Table XXX-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXX-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXX-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH
XXX-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH
XXX-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH
XXX-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH
XXX-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH
XXX-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH
XXX-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH
XXX-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 599 of 739

Table XXX-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH
XXX-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH
XXX-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH
XXX-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 600 of 739

Table XXX-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 601 of 739

Table XXX-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	H	OH
XXX-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH
XXX-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH
XXX-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH
XXX-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH
XXX-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH
XXX-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 602 of 739

Table XXX-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-31-1	CH_3	H	H	H	^nBu	H	F	H	OH
XXX-31-2	CH_3	H	H	CH_3	^nBu	H	F	H	OH
XXX-31-3	CH_3	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-31-5	CH_3	H	H	CH_2Ph	^nBu	H	F	H	OH
XXX-31-6	CH_3	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXX-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXX-31-8	CH_3	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-32-1	Et	H	H	H	^nBu	H	F	H	OH
XXX-32-2	Et	H	H	CH_3	^nBu	H	F	H	OH
XXX-32-3	Et	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-32-5	Et	H	H	CH_2Ph	^nBu	H	F	H	OH
XXX-32-6	Et	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXX-32-7	Et	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXX-32-8	Et	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-33-1	^iPr	H	H	H	^nBu	H	F	H	OH
XXX-33-2	^iPr	H	H	CH_3	^nBu	H	F	H	OH
XXX-33-3	^iPr	H	H	$CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-33-4	^iPr	H	H	$CH_2CH(CH_3)_2$	^nBu	H	F	H	OH
XXX-33-5	^iPr	H	H	CH_2Ph	^nBu	H	F	H	OH
XXX-33-6	^iPr	H	H	CH_2-indol-3-yl	^nBu	H	F	H	OH
XXX-33-7	^iPr	H	H	$CH_2CH_2SCH_3$	^nBu	H	F	H	OH
XXX-33-8	^iPr	*	H	*	^nBu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 603 of 739

Table XXX-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH
XXX-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 604 of 739

Table XXX-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 605 of 739

Table XXX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXX-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-42-1	Et	H	H	H	Bz	H	F	H	OH
XXX-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 606 of 739

Table XXX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXX-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXX-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXX-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-45-8	Ph	*	H	*	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 607 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXX-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 608 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXX-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 609 of 739



XXXI

Table XXXI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXXI-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXXI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXXI-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXXI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-3.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 610 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXXI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXXI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXXI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXXI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXXI-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 611 of 739

Table XXXI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 612 of 739

Table XXXI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXXI-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXXI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 613 of 739

Table XXXI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-12-1	Et	H	H	H	Et	H	F	F	OH
XXXI-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXXI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXXI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXXI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXXI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXXI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 614 of 739

Table XXXI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-15-1	Ph	H	H	H	Et	H	F	F	OH
XXXI-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXXI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXXI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 615 of 739

Table XXXI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXXI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXXI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXXI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 616 of 739

Table XXXI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXXI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXXI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXXI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 617 of 739

Table XXXI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXXI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 618 of 739

Table XXXI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 619 of 739

Table XXXI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXXI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXXI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 620 of 739

Table XXXI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXXI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXXI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 621 of 739

Table XXXI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 622 of 739

Table XXXI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXXI-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXXI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 623 of 739

Table XXXI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-42-1	Et	H	H	H	Bz	H	F	F	OH
XXXI-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXXI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXXI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXXI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXXI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXXI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 624 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXXI-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXXI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXXI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 625 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXXI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXXI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XXXI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXXI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 626 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXXII

Table XXXII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXXII-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXXII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXXII-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXXII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 627 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXXII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXXII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXXII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXXII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-5-1	Ph	H	H	H	CH_3	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 628 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-8.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 629 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 630 of 739

Table XXXII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXXII-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXXII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-12-1	Et	H	H	H	Et	H	H	F	OH
XXXII-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXXII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXXII-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXXII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 631 of 739

Table XXXII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXXII-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXXII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXXII-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXXII-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 632 of 739

Table XXXII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXXII-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXXII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXXII-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 633 of 739

Table XXXII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXXII-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXXII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXXII-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 634 of 739

Table XXXII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXXII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXXII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 635 of 739

Table XXXII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 636 of 739

Table XXXII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXXII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 637 of 739

Table XXXII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXXII-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXXII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXXII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 638 of 739

Table XXXII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 639 of 739

Table XXXII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 640 of 739

Table XXXII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXXII-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXXII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXXII-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXXII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXXII-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXXII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 641 of 739

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXXII-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXXII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXXII-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXXII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 642 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXXII-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXXII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXXII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 643 of 739

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXXII-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

DOSAGE, ADMINISTRATION, AND USE

A sixth embodiment of the present invention is directed to a composition for the treatment of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, that is intended to include its salts (acid or basic addition salts), hydrates, solvates, and crystalline forms can be obtained, represented by formula **I**.

It is contemplated that the formulation of the sixth embodiment can contain any of the compounds contemplated in any of the aspects of the first, second, third, fourth, and fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention.

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, hard and soft gelatin capsules, solutions, emulsions, syrups, or

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 644 of 739

suspensions. Compounds of the present invention are efficacious when administered by suppository administration, among other routes of administration. The most convenient manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the severity of the disease and the patient's response to the antiviral medication.

A compound or compounds of the present invention, as well as their pharmaceutically acceptable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as suspensions, emulsions, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is used to prepare a pharmaceutical composition, and is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 645 of 739

absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound as used herein means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as glycolic acid, pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, salicylic acid, muconic acid, and the like or (2) basic addition salts formed with the conjugate bases of any of the inorganic acids listed above, wherein the conjugate bases comprise a cationic component selected from among Na^+, K^+, Mg^{2+}, Ca^{2+}, and $NH_gR'''_{4-g}{}^+$, in which R''' is a C_{1-3} alkyl and g is a number selected from among 0, 1, 2, 3, or 4. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.

Solid form preparations include powders, tablets, pills, capsules, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 646 of 739

thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs and aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Suitable formulations along with pharmaceutical carriers, diluents and expcipients are described in *Remington: The Science and Practice of Pharmacy* **1995,** edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania, which is hereby incorporated by reference. The compounds of the present invention can also be encapsulated in liposomes, such as those disclosed in U.S. Patent Nos. 6,180,134, 5,192,549, 5,376,380, 6,060,080, 6,132,763, each of which is incorporated by reference. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 647 of 739

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (e.g., salt formulation), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

A seventh embodiment of the present invention is directed to a use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any condition the result of an infection by any one of the following viral agents: hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus.

The term "medicament" means a substance used in a method of treatment and/or prophylaxis of a subject in need thereof, wherein the substance includes, but is not limited to, a composition, a formulation, a dosage form, and the like, comprising the compound of formula **I**. It is contemplated that the compound of the use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any of the antiviral conditions disclosed herein of the seventh embodiment can be any of the compounds contemplated in any of the aspects of the first, second, third, fourth, fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention. A medicament includes, but is not limited to, any one of the compositions contemplated by the sixth embodiment of the present invention.

A eighth embodiment of the present invention is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective amount of the compound represented by formula I to the subject.

A first aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective of at least two or more different compounds falling within the scope of the compound represented by formula I to the subject.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 648 of 739

A second aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least two compounds falling within the scope of the compound represented by formula I to the subject.

It is intended that a subject in need thereof is one that has any condition the result of an infection by any of the viral agents disclosed herein, which includes, but is not limited to, hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus, flaviviridae viruses or pestiviruses or hepaciviruses or a viral agent causing symptoms equivalent or comparable to any of the above-listed viruses.

The term "subject" means a mammal, which includes, but is not limited to, cattle, pigs, sheep, chicken, turkey, buffalo, llama, ostrich, dogs, cats, and humans, preferably the subject is a human. It is contemplated that in the method of treating a subject thereof of the sixth embodiment can be any of the compounds contemplated in any of the aspects of the first, second, and third embodiments or those specifically recited in the tables above, either alone or in combination with another compound of the present invention.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.1 and about 10 g, including all values in between, such as 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5, per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.5 and about 7.5 g per day, more preferred 1.5 and about 6.0 g per day. Generally, treatment is initiated with a large initial "loading dose" to rapidly reduce or eliminate the virus following by a decreasing the dose to a level sufficient to prevent

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 649 of 739

resurgence of the infection. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

Therapeutic efficacy can be ascertained from tests of liver function including, but not limited to protein levels such as serum proteins (e.g., albumin, clotting factors, alkaline phosphatase, aminotransferases (e.g., alanine transaminase, aspartate transaminase), 5'-nucleosidase, γ-glutaminyltranspeptidase, etc.), synthesis of bilirubin, synthesis of cholesterol, and synthesis of bile acids; a liver metabolic function, including, but not limited to, carbohydrate metabolism, amino acid and ammonia metabolism. Alternatively the therapeutic effectiveness may be monitored by measuring HCV-RNA. The results of these tests will allow the dose to be optimized.

A third aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of a compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours. Examples of "another antiviral agents" include, but are not limited to: HCV NS3 protease inhibitors (see WO 2008010921, WO 2008010921, EP 1881001, WO 2007015824, WO 2007014925, WO 2007014926, WO 2007014921, WO 2007014920, WO 2007014922, US 2005267018, WO 2005095403, WO 2005037214, WO 2004094452, US 2003187018, WO 200364456, WO 2005028502, and WO 2003006490); HCV NS5B Inhibitors (see US 2007275947, US20072759300, WO2007095269, WO 2007092000, WO 2007076034, WO 200702602, US 2005-98125, WO 2006093801, US 2006166964, WO 2006065590, WO 2006065335, US 2006040927, US 2006040890, WO 2006020082, WO 2006012078, WO 2005123087, US 2005154056, US 2004229840, WO 2004065367, WO 2004003138, WO 2004002977, WO 2004002944, WO 2004002940, WO 2004000858, WO 2003105770,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 650 of 739

WO 2003010141, WO 2002057425, WO 2002057287, WO 2005021568, WO 2004041201, US 20060293306, US 20060194749, US 20060241064, US 6784166, WO 2007088148, WO 2007039142, WO 2005103045, WO 2007039145, WO 2004096210, and WO 2003037895); HCV NS4 Inhibitors (see WO 2007070556 and WO 2005067900); HCV NS5a Inhibitors (see US 2006276511, WO 2006120252, WO 2006120251, WO 2006100310, WO 2006035061); Toll-like receptor agonists (seeWO 2007093901); and other inhibitors (see WO 2004035571, WO 2004014852, WO 2004014313, WO 2004009020, WO 2003101993, WO 2000006529).

A fourth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of a compound represented by formula **I** and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

A fifth aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of at least one compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

A sixth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least one compound represented by formula **I** and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 651 of 739


including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

It is contemplated that the another antiviral agent includes, but is not limited to interferon -α , interferon-β, pegylated interferon-α, ribavirin, levovirin, viramidine, another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. When the active compound or its derivative or salt are administered in combination with another antiviral agent the activity may be increased over the parent compound. When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the nucleoside derivatives. "Concurrent administration" as used herein thus includes administration of the agents at the same time or at different times. Administration of two or more agents at the same time can be achieved by a single formulation containing two or more active ingredients or by substantially simultaneous administration of two or more dosage forms with a single active agent.


It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions. Furthermore, the term "treatment" of a HCV infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by HCV infection, or the clinical symptoms thereof.

PROCESS FOR PREPARATION

An ninth embodiment of the present invention is directed to a process for preparing the compound of formula I, which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4




5

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 652 of 739


wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, and base have their meanings as disclosed in the Detailed Description of the Invention and X' is a leaving group, such as Cl, Br, I, tosylate, mesylate, trifluoroacetate, trifluorosulfonate, pentafluorophenoxide, p-NO_2-phenoxide, or other commonly used leaving groups as disclosed in *Advanced Organic Chemistry* by March, Fourth Edition. Leaving groups and methods that can be used to effect the formation of a phosphoramidate nucleoside conjugate are found in US 20060142238 and WO 2007095269. Preferably, the leaving group is Cl.

This reaction is performed in an anhydrous aprotic solvent such tetrahydrofuran, dioxane, or both tetrahydrofuran and dioxane, or any functional equivalent thereof, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, collidine, pyridine, 2,6-lutidine, 2, 6-^{t}Bu-pyridine, etc. a tertiary amine base, such as triethylamine, diisopropylethylamine, etc., or an alkyl Grignard reagent, such as tBuMgCl, tBuMgBr, MeMgCl, MeMgBr, etc. The phosphorochloridate (3-10 equivalents) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

A tenth embodiment of the present invention is directed to a product obtained by a process which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 653 of 739

wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, X', and base have their meanings as disclosed in the Detailed Description of the Invention.

This reaction can be performed in an anhydrous aprotic solvent or other suitable solvent, such as tetrahydrofuran, dioxane, or a mixture of tetrahydrofuran and dioxane, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, a tertiary amine base or tButyl Magnesium Chloride. A phosphorochloridate (3-10 equivalents (or suitable "phosphoro-(leaving group)-date")) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

Compounds and Preparation


Phosphoramidate compounds of the present invention can be prepared by condensation of a nucleoside analog **5** with a suitably substituted phosphochloridate compound **4** (Scheme 1). The nucleoside analog is made by conventional procedures disclosed in any one of U.S. Published Application Nos. 2005/0009737, 2006/0199783, 2006/0122146, and 2007/0197463, each of which is incorporated by reference in its entirety.

Disclosed 1H-NMR values were recorded on a Varian AS-400 instrument. Mass spectral data were obtain using either a Micromass-Quattromicro API or a Waters Acquity.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 654 of 739

Thus, by way of example only, a suitably substituted phenol can be reacted with phosphorus oxychloride (**1**) to afford an aryloxy phosphorodichloridate **2** (see Example 1) which is subsequently treated with a acid addition salt of an α-amino acid ester in the presence of TEA to afford an aryloxy phosphorochloridate **4**. This arylalkoxy-amino acid phosphoramidate is reacted with the nucleoside analog to provide the product **I** (for procedure see, e.g., C. McGuigan et al. Antiviral Res. 1992 17:311-321; D. Curley et al. Antiviral Res. 1990 14:345-356; McGuigan et al. Antiviral Chem. Chemother 1990 1(2):107-113).

Scheme 1



The preparation of nucleoside phosphoramidates requires reacting an appropriately substituted phosphochloridate with a nucleoside containing a free 5'-hydroxyl moiety. In cases where only one hydroxyl group is present, preparation of the phosphoramidate usually proceeds smoothly when the phosphochloridate is reacted with

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 655 of 739


the desired nucleoside. In cases where the nucleoside contains more than one free hydroxyl group, preparation of the appropriately protected nucleoside might be required. Silyl, acetonide or other alcohol protecting groups known in the art might be warranted for protection of the sugar moiety. For protection of the nucleoside base, protecting a free amino group may require amidine protection strategy.

Condensation of the phosphochloridate can be carried out on the unprotected nucleoside. Since the 5'-OH group of a nucleoside is much less hindered than the 3'-OH group, selective phosphoramidation is possible under carefully controlled conditions. After condensation to form a protected phosphoramidate nucleoside, deprotection to obtain the free phosphoramidate nucleoside can be carried out using standard protocols for nucleic acid chemistry. In many cases, the desired product is readily separated from the starting material using column chromatography on silica gel. The synthetic scheme is summarized in Scheme 1.

A further understanding of the disclosed embodiments will be appreciated by consideration of the following examples, which are only meant to be illustrative, and not limit the disclosed invention.

EXAMPLE 1

General Procedure for Preparation of phosphorodichloridates



1 2


A solution of the appropriate phenol **R^1-OH** (1eq) and triethylamine (1 eq.) in anhydrous ether was added dropwise to a stirred solution of phosphoryl trichloride **1** (1eq) at 0 °C over a period of 3 hours under nitrogen. Then the temperature was warmed to room temperature, and the reaction was stirred overnight. The triethylamine salt was

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 656 of 739

quickly removed with suction filtration and the filtrate concentrated *in vacuo* to dryness to afford **2** as an oil which was used without further purification.

EXAMPLE 2

General Procedure for Preparation of phosphorochloridates




2 **3** **4**

A solution of triethylamine (2eq) in anhydrous dichloromethane was added dropwise to a solution of aryloxy-phosphodichloridate **2** (1 eq) and the appropriate amino ester **3** (1 eq) in anhydrous dichloromethane with vigorous stirring at -78 °C over a period of 30 to 120 minutes. Then the reaction temperature was allowed to warm to room temperature and stirred over night. Solvent was removed. The residue was washed with ethyl ether and filtered, the filtrate was dried over reduced pressure to give **4**.

EXAMPLE 3

General Procedures for nucleoside phosphoramidate derivatives




4 **5** **I**

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 657 of 739

A solution of the appropriate phosphorochloridate **4** (6.5 equivalents) in anhydrous tetrahydrofuran (THF) was added to a mixture of nucleoside **5** (1 equivalent) and N-methylimidazole (8 equivalents) in anhydrous THF with vigorous stirring at room temperature and the reaction mixture was stirred overnight. The solvent was removed *in vacuo* and the crude was purified by column chromatography and/or preparative thin layer chromatography to give **I**.

EXAMPLE 4

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine



2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (1.0g, 1 eq) (Clark, J., et al., J. Med. Chem., 2005, 48, 5504-5508) was dissolved in 10 ml of anhydrous pyridine and concentrated to dryness in vacuo. The resulting syrup was dissolved in 20 ml of anhydrous pyridine under nitrogen and cooled to 0°C with stirring. The brown solution was treated with benzoyl chloride (1.63g, 3eq) dropwise over 10 min. The ice bath was removed and stirring continued for 1.5h whereby thin-layer chromatography (TLC) showed no remaining starting material. The mixture was quenched by addition of water

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 658 of 739

(0.5 ml) and concentrated to dryness. The residue was dissolved in 50 mL of dichloromethane (DCM) and washed with saturated $NaHCO_3$ aqueous solution and H_2O. The organic phase was dried over $NaSO_4$ and filtered, concentrated to dryness to give N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0 g, Yield: 91%).


N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0g, 1 eq) was refluxed in 80% aqueous AcOH overnight. After cooling and standing at room temperature (15 °C), most of the product precipitated and then was filtered through a sintered funnel. White precipitate was washed with water and co-evaporated with toluene to give a white solid. The filtrate was concentrated and co-evaporated with toluene to give additional product which was washed with water to give a white solid. Combining the two batches of white solid gave 1.50g of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (Yield: 91%).

To a solution of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (1.5 g, 1eq) in MeOH (10 mL) was added a solution of saturated ammonia in MeOH (20mL). The reaction mixture was stirred at 0 °C for 30 min, and then warmed to room temperature slowly. After the reaction mixture was stirred for another 18 hours, the reaction mixture was evaporated under reduced pressure to give the residue, which was purified by column chromatography to afford pure compound 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (500 mg, Yield: 60 %).

EXAMPLE 5

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate)


Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 659 of 739



Phenyl methoxyalaninyl phosphorochloridate (1 g, 6.5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (50.1 mg, 15.6%). ^{1}H NMR (DMSO-d_6) δ 1.20-1.27 (m, 6H), 3.58 (d, J = 16.0 Hz, 3H), 3.75-3.92 (m, 2H), 4.015-4.379 (m, 2H), 5.54 (t, J = 10.2 Hz, 1H), 5.83-5.91 (m, 1H), 6.00-6.16 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.22 (s, 1H), 7.35 (t, J = 4.4 Hz, 2H), 7.55 (s, 1H), 11.52 (s, 1H); MS, *m/e* 502 $(M+1)^+$.

EXAMPLE 6

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate)




Phenyl methoxy-valyl phosphorochloridate (0.6 g, 3.6 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.44 g, 9 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 660 of 739

pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (60 mg, 20%). ^{1}H NMR (DMSO-d_6) δ 0.74-0.847 (m, 6H), 1.20-1.28 (m, 3H), 1.89-1.92 (m, 1H), 3.50-3.54 (m, 1H), 3.58 (d, J = 10.4Hz, 3H), 3.72-3.95 (m, 1H), 4.03-4.05 (m, 1H), 4.23-4.43 (m, 2H), 5.56 (t, J = 16.0 Hz, 1H), 5.85-5.92 (m, 1H), 6.01-6.07 (m, 1H), 7.16-7.21 (m, 3H), 7.37 (t, J = 8 Hz, 2H), 7.55-7.60 (m, 1H), 11.52 (s, 1H); MS, *m/e* 530 $(M+1)^+$.

EXAMPLE 7

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1 g, 3.4 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.2 g,1 eq) and N-methylimidazole (0.35 g, 6 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed reduced pressure to give the desired product (120 mg, 26%). ^{1}H NMR (DMSO-d_6) δ 0.72-0.82 (m, 6H), 1.19-1.26 (m, 3H),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 661 of 739

1.86-1.92 (m, 1H), 3.48-3.50 (m, 1H), 3.56 (d, J = 12.0 Hz, 3H), 3.72-3.89 (m, 1H), 3.96-4.03 (m, 1H), 4.22-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.85-5.91 (m, 1H), 5.98-6.13 (m, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.49-7.56 (m, 3H), 11.53 (s, 1H); MS, *m/e* 608 $(M+1)^+$.

EXAMPLE 8

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate)




4-Bromophenyl methoxy-alanyl phosphorochloridate (0.6 g, 5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq)and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (40 mg, 12 %); ^{1}H NMR (DMSO-d_6) δ 1.20-1.26 (m, 6H), 3.57 (d, J = 2.8 Hz, 3H), 3.84 (s, 1H), 3.97-4.03 (m, 1H), 4.21-4.25 (m, 1H), 4.33-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.83-5.89 (m, 1H), 5.98-6.19 (m, 1H), 7.16 (t, J = 10.2 Hz, 2H), 7.52-7.57 (m, 3H), 11.52 (s, 1 H); MS, *m/e* 580$(M+1)^+$.

EXAMPLE 9

Preparation of N^4-(*N*,*N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine


Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 662 of 739



2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (500 mg, 1.9 mmol) was stirred with dimethylformamide dimethyl acetal in DMF (10 mL). The resulting mixture was stirred at room temperature overnight. After solvent removal the crude product was used for next step without further purification.

EXAMPLE 10

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-alanyl phosphate)




Phenyl methoxyalaninyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (62 mg, 20.6%). ^{1}H NMR (DMSO-d_6) δ 1.16 (d, J = 23.2 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H), 3.56 (S, 3H), 3.69-3.75 (d, J = 25.6 Hz, 1H), 3.82-3.86 (m, 1H), 3.96-3.98 (m, 1H), 4.21-4.34 (m, 2H), 5.68 (d, J = 7.2 Hz, 1H), 5.75-5.77 (m, 1H), 6.07-6.16 (m, 1H), 7.15-7.19 (m, 3H), 7.2 (d, J = 9.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.48 (d, J = 9.2 Hz, 1H); MS, *m/e* 501(M+1)$^+$.

EXAMPLE 11

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 663 of 739

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1.0 g, 3.4 eq.) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.2 g,1 eq.) and N-methylimidazole (0.35 g, 6 eq.) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (59 mg, 13%); ^{1}H NMR (DMSO-d_6) δ 0.74-0.83 (m, 6H), 1.12-1.20 (m, 3H), 1.89-1.92 (m, 1H), 3.49-3.51 (m, 1H), 3.55 (s, 3H), 3.59-3.68 (m, 1H), 3.72-.383 (m, 1H), 4.21-4.39 (m, 2H), 5.70-5.72 (m, 1H), 5.76-5.83 (m, 1H), 6.04-6.16 (m, 1H), 7.15 (d, *J* = 13.0 Hz, 2H), 7.26 (s, 1H), 7.33 (s, 1H), 7.46-7.55 (m, 1H), 7.56 (d, *J* = 4.4 Hz, 2H) ; MS, *m/e* 607 $(M+1)^+$.

EXAMPLE 12

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate)


Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 664 of 739



Phenyl methoxy-valyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (86 mg, 42.9 %). ^{1}H NMR (DMSO-d_6) δ 0.72-0.80 (m, 6H), 1.09-1.18 (m, 3H), 1.87-1.92 (m, 1H), 3.47-3.51 (m, 1H), 3.58 (s, 3H), 3.71-3.75 (m, 1H), 3.97 (t, *J* = 11.2 Hz,1H), 4.22-4.37 (m, 2H), 5.70 (d, *J* = 8.0 Hz,1H), 5.76-5.84 (m, 1H), 6.01-6.15 (m, 1H), 7.13-7.18 (m, 3H), 7.27 (s, 2H), 7.34 (d, *J* = 4.0 Hz, 2H), 7.46-7.50 (m, 1H); MS, *m/e* 529 $(M+1)^+$.

EXAMPLES

Example numbers **13-54** and **56-66** are prepared using similar procedures described for examples **5-8.** The example number, compound identification, and NMR/MS details are shown below:



Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 665 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
13	Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.16 (m, 3H), 1.20-1.28(m,6H), 3.70-3.90 (m, 2H), 4.00-4.08 (m, 3H), 4.18-4.45 (m, 2H), 5.52-5.58 (m, 1H), 5.85-5.98 (m, 1H), 6.00-6.20 (m, 2H), 7.16-7.23 (m, 3H), 7.37-7.40 (m, 2H) , 7.54-7.60 (m, 1H), 11.54 (s.1H) ; MS, m/e 516.1 (M+1)+
14	1-Napth	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.18-1.30 (m, 6H), 3.78-4.10 (m, 3H), 4.38-4.49 (m, 2H), 4.99-5.11 (m, 2H), 5.28-5.40 (m, 1H), 5.85-6.10 (m, 2H), 6.30-6.41 (m, 1H), 7.28-7.32 (m, 5H), 7.41-7.60 (m, 5H), 7.73-7.76(m, 1H) , 7.94-8.11(m, 1H) , 8.13-8.15(m, 1H) , 11.50 (s.1H) ; MS, m/e 628.4 (M+1)+
15	Ph	H	H	H	Me	1H NMR (DMSO-d_6) δ 1.22 (d, J=22.4 Hz, 3H), 3.59(s, 3H), 3.63-3.69 (m, 2H), 3.74-3.8(m, 1H), 4.02(d, J=11.2 Hz, 1H), 4.23-4.28(m, 1H), 4.40-4.43 (m, 1H), 5.57-5.60 (m, 1H), 5.89(d, J=6.8 Hz, 1H), 6.00-6.06(m, 2H), 7.15-7.23 (m, 3H), 7.35-7.39 (m, 2H),7.52(d, J=8 Hz, 1H), 11.52(s, 1H) ; MS, m/e 487.97 (M+1)+
16	2,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.57-3.60 (m, 3H), 3.84-3.92 (m, 2H), 4.00-4.04 (m, 1H), 4.31-4.44 (m, 2H), 5.54-5.61 (m, 1H), 5.85-6.10 (m, 2H), 6.32-6.43 (m, 1H), 7.44-7.54 (m, 3H), 7.72-7.75 (m, 1H), 11.54 (s.1H) ; MS, m/e 570.2 (M+1)+
17	1-Napth	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.15-1.27 (m, 6H), 3.51-3.55 (d, 3H), 3.85-3.96 (m, 2H), 4.00-4.10(m, 1H), 4.30-4.46 (m, 2H), 5.31-5.39 (m, 1H), 5.89-6.05 (m, 2H), 6.22-6.34 (m, 1H), 7.44-7.60 (m, 5H), 7.73-7.77 (m, 1H), 7.93-7.96 (m, 1H), 8.12-8.14 (m, 1H),11.50(s.1H) ; MS, m/e 552.1 (M+1)+
18	Ph	*	H	*	Me	1H NMR (DMSO-d_6) δ 1.19 (d, J=22.8 Hz, 3H), 1.69-1.84 (m, 3H), 1.99-2.04 (m, 1H), 3.16-3.21 (m, 2H), 3.58 (s, 3H), 3.68-3.8 (m, 1H), 4.00 (m, 1H), 4.01-4.13 (m, 1H), 4.22-4.25 (m, 1 H), 4.5 (d, J = 11.2 Hz, 1H), 5.54 (d, J = 8.0 Hz, 1H), 5.86 (s, 1H), 5.6 (d, J = 19.6 Hz, 1H), 7.15-7.2 (m, 3H), 7.34 (t, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 1H), 11.38 (s, 1H) ; MS, m/e 527.93(M+1)+
19	Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.80-0.90 (m, 3H), 1.20-1.35 (m, 8H), 1.48-1.55 (m, 2H), 3.78-3.88 (m, 2H), 3.95-4.08 (m, 3H), 4.22-4.45 (m, 2H), 5.55-5.57(t, 1H), 5.85-6.18 (m, 3H), 7.14-7.23 (m, 3H), 7.35-7.40 (m, 2H), 7.51-7.60 (d, 1H), 11.50 (s.1H) ; MS, m/e 544.2 (M+1)+
20	Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.20-1.30 (m, 6H), 3.72-4.05 (m, 3H), 4.23-4.27 (m, 1H), 4.32-4.45 (m, 1H), 5.07-5.10(t, 2H), 5.52-5.56(t , 1H), 5.86-6.10 (m, 2H), 6.13-6.21(m,1H), 7.15-7.21 (m, 3H), 7.29-7.40 (m, 7H), 7.51-7.56 (d, 1H), 11.50 (s.1H) ; MS, m/e 578.2 (M+1)+
21	4-F-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.28-1.34 (m, 6H), 3.65(d, J= 4 Hz, 3H), 3.85-3.96 (m, 2H), 4.06-4.12 (m, 1H), 4.30-4.34 (m,1H), 4.40-4.47 (m, 1H), 5.62-5.67 (m, 1H), 5.94-6.01(m, 1H), 6.09 (d, J=18.8 Hz, 1H), 6.17-6.26 (m, 1H), 7.27-7.33(m, 4H), 7.62 (d, J = 7.6 Hz, 1H), 11.61 (s, 1H) ; MS, m/e 519.94(M+1)+
22	4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.58 (d, 2H), 3.70-3.95(m,2H), 3.95-4.08 (m,1H), 4.23-4.45 (m, 2H), 5.55-5.61(t , 1H),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 666 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						5.85-6.10 (m, 2H), 6.15-6.23(m,1H), 7.20-7.26 (m, 2H), 7.43-7.46 (m, 2H), 7.54-7.57 (d, 1H), 11.50 (s.1H) ; MS, m/e 536.1 (M+1)+
23	3,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.13 (m, 6H), 3.49 (s, 3H), 3.61-3.85 (m, 2H), 3.90-3.93 (m, 1H), 4.16-4.22 (m, 1H), 4.27-4.31 (m, 1H), 5.47-5.52 (m, 1H), 5.82 (d, J = 11.6 Hz, 1H), 5.93(d, J = 19.2 Hz, 1H), 6.15-6.25 (m, 1H), 7.13 (t, J = 9.6 Hz, 1H), 7.43 (d, J = 12Hz, 2H), 7.57 (d, J = 6.0 Hz, 1H), 11.43(s, 1H) ; MS, m/e 569.85 (M+1)+
24	Ph	H	H	Me	2-Bu	1H NMR (DMSO-d_6) δ 0.83 (d, J = 6.8 Hz, 6H), 1.20-1.26 (m, 6H), 1.79-1.86 (m, 1H), 3.73-3.90 (m, 4H), 4.01 (t, J = 11.2 Hz, 1H), 4.21-4.28 (m, 1H), 4.33-4.42 (m, 1H), 5.54 (t, J = 7.6 Hz, 1H), 5.85-5.92 (m, 1H), 5.99-6.13 (m, 2H), 7.19 (t, J = 8 Hz, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 11.52 (s, 1H) ; MS, m/e 544.00 (M+1)+
25	Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.28 (m, 12H), 3.74-3.81 (m, 2H), 3.95-4.08 (m,1H), 4.20-4.45 (m, 2H), 4.83-4.87 (m, 1H), 5.52-5.58 (m, 1H), 5.84-6.15 (m, 3H), 7.17-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.54-7.57 (m, 1H), 11.50 (s.1H) ; MS, m/e 530.2 (M+1)+
26	4-MeO-Ph	H	H	Me	n-Bu	1HNMR (400MHz, DMSO-d_6): δ =0.78-0.82 (m, 3H), 1.29-1.47 (m, 8H), 1.49-1.54 (m, 2H), 3.66-3.87 (m, 5H), 3.96-4.02 (m, 3H), 4.21-4.39 (m, 2H), 5.57 (t, J= 12.0Hz, 1H), 5.84-6.05 (m, 3H), 6.90 (dd, J1 =8.0Hz, J2=4.0Hz, 2H), 7.09-7.14 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.55 (d, J =8.0Hz, 1H), 11.48-11.62 (s, 1H)
27	4-F-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.28 (m, 9H), 3.72-3.94(m,2H) ,3.98-4.10 (m,3H), 4.21-4.42(m,2H), 5.55-5.61 (t, 1H), 5.85-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 533.90 (M+1)+
28	4-F-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.30 (m, 12H), 3.74-3.85(m,2H) ,3.98-4.06 (m,1H), 4.23-4.41(m,2H), 4.83-4.87 (m, 1H), 5.55-5.61 (t, 1H), 5.85-6.12 (m, 3H), 7.18-7.24 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 547.91 (M+1)+
29	4-F-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.10-1.23 (m, 6H), 3.65-3.89(m,3H) ,4.10-4.30 (m,2H), 4.96-5.00(m,2H), 5.46-5.50 (t, 1H), 5.75-5.96 (m, 2H), 6.04-6.12(m,1H), 7.05-7.11 (m,4H), 7.20-7.24 (d, 5H), 7.42-7.45(d,1H), 11.50 (s.1H) ; MS, m/e 595.94 (M+1)+
30	4-MeO-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ=1.15-1.27 (m, 12H), 3.71-3.89 (m, 5H), 3.98-4.02 (m, 1H), 4.22-4.25 (m, 1H), 4.33-4.39 (m, 1H), 4.84-4.87 (m, 1H), 5.57 (t, J= 12.0Hz, 1H), 5.91-6.03 (m, 3H), 6.90 (d, J= 8.0Hz, 2H), 7.09-7.14 (m, 2H), 7.55 (d, J= 8.0Hz, 1H), 11.51 (s, 1H)
31	2-Cl-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.23 (m, 6 H), 3.93-4.00 (m, 3 H), 4.27-4.40 (m, 2H), 5.0(t, J= 7.2 Hz, 2 H), 5.53 (m ,1 H), 5.80-6.0(m , 2 H), 6.30(m, 1H), 7.15 (d, J= 2.4 Hz, 1 H), 7.27 (m, 6 H), 7.51 (m, 3 H), 11.5 (s, 1 H) ; MS, m/e 579.87(M+1)+ / 596.78 (M+18)+
32	2,4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ=0.82 (m, 3 H),1.23 (m, 8 H) , 1.47 (m, 2 H), 3.86 (m, 2 H), 3.84 (m, 3 H),4.27-4.43 (m, 2H), 5.5 (m , 1 H), 6.02 (m ,2 H), 6.35(m, 1H), 7.44 (m, 3 H), 7.77 (m, 1 H), 11.5 (s, 1 H) ; MS, m/e 611.87(M+1)+
33	4-Me-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.14-1.27 (m, 12H), 2.17-2.26 (m, 3H), 3.73-3.82 (m, 1H), 3.99-4.02 (m, 1H), 4.23-4.26 (m, 1H), 4.37-4.40 (m,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 667 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						1H), 4.82-4.88 (m, 1H), 5.52-5.58 (m, 1H), 5.85-6.07 (m, 3H), 7.01-7.20 (m, 4H), 7.55 (d, J = 16Hz, 1H), 11.51 (s, 1H) ; MS, m/e 543.98 (M+1)+; 1108.86 (2M+23)+
34	4-F-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.82-0.89 (m,3H), 1.20-1.31 (m, 8H), 1.48-1.53 (m,2H), 3.77-3.90 (m,2H) ,3.95-4.10 (m,3H), 4.21-4.45(m,2H), 5.56-5.61 (t, 1H), 5.83-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 584.1 (M+23)+
35	3,4-diCl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ1.12-1.31 (m, 9H), 3.77-3.92 (m,2H), 3.95-4.08 (m,3H), 4.21-4.45(m,2H), 5.56-5.62 (t, 1H), 5.80-6.11 (m, 2H), 6.18-6.33(m,1H), 7.18-7.25 (m,1H), 7.49-7.56 (d, 2H), 7.62-7.67(m,1H), 11.50 (s.1H) ; MS, m/e 606.1 (M+23)+
36	2-Cl-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ =1.12-1.16 (m, 6H), 1.21-1.27 (m, 6H), 3.79-3.85 (m, 2H), 4.00-4.07 (m, 1H), 4.28-4.32 (m, 1H), 4.38-4.43 (m, 1H), 4.83-4.87 (m, 1H), 5.56 (dd, J1=16.0Hz, J2=8.0Hz, 1H), 5.85-6.12 (m, 2H), 6.20-6.33 (m, 1H), 7.19-7.22 (m, 1H), 7.33 (t, J= 16.0Hz, 1H), 7.48-7.55 (m, 3H), 11.55 (s, 1H)
37	4-MeO-Ph	H	H	Me	Bn	1HNMR(400MHz, DMSO-d_6): δ=1.19-1.26 (m, 6H), 3.69-3.70 (s, 3H), 3.87 (m, 2H), 3.99 (m, 1H), 4.20-4.21 (m, 1H), 4.35 (m, 1H), 5.07-5.09 (m, 2H), 5.54 (t, J = 16.0Hz, 1H), 5.85-5.92 (m, 1H), 6.04-6.10 (m, 2H), 6.86 (d, J= 8.0Hz, 2H), 7.09 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.30-7.34 (m, 5H), 7.53 (s, 1H), 11.52 (s, 1H)
38	Ph	H	H	Me	n-Pen	1H NMR (DMSO-d_6) δ 0.79-0.81 (m, 3H), 1.17-1.23 (m, 10H), 3.74-3.81 (m, 2H), 3.94-3.96 (m, 3H), 4.19-4.36 (m, 2H), 5.49-5.54 (m, 1H), 5.87-6.08 (m,3H), 7.14-7.33 (m, 3H), 7.31-7.35 (m, 2H), 7.51 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 557.9 (M+1)+; 1136.88 (2M+23)+
39	4-Cl-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.04-1.19 (m, 12H), 3.76-3.80 (m , 2H), 3.98-4.08 (m, 1H), 4.42-4.42 (m, 2H), 4.82-4.85 (m, 1H), 5.55-5.60 (m, 1H), 5.80-6.20 (m,3H),7.20-7.2 5(m, 2H), 7.43 (d, J = 8.8Hz, 1H), 7.54 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 563.88 (M+1)+; 1148.73 (2M+23)+
40	4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.85 (t, J = 7.2 Hz, 3H), 1.22-1.33 (m, 8H),1.45-1.53 (m, 2H), 3.80-3.87 (m, 2H), 3.96-4.04 (m, 3H), 4.24-4.27 (m, 1H), 4.35-4.39 (m, 1H), 5.56-5.61 (m, 1H), 5.82-6.11 (m, 2H), 6.15-6.18 (m, 1H), 7.20-7.56 (m, 4H), 7.51-7.57 (m.1H) , 11.54 (s, 1H); MS, m/e577.95(M+1)+
41	4-Cl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.14 (t, J = 7.0Hz, 3H), 1.20-1.28 (m, 6H),3.77-3.88 (m, 2H), 3.99-4.07 (m, 3H), 4.24-4.28 (m, 1H), 4.34-4.43 (m, 1H), 5.56-5.61 (m, 1H), 5.86-6.13 (m, 2H), 6.15-6.24 (m, 1H), 7.20-7.26 (m, 2H), 7.44 (d, J = 7.6Hz, 2H) , 7.55 (d, J = 7.6Hz, 1H), 11.55 (s, 1H); MS, m/e549.11(M+1)+
42	4-Me-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.79-0.83 (m, 3H), 1.17-1.28 (m, 8H), 1.45-1.47 (m, 2H), 2.22 (d, J = 2.8Hz, 1H), 3.70-3.90 (m, 2H), 3.95-3.98 (m, 3H), 4.10-4.40 (m, 2H), 5.51 (t, 1H), 5.80-5.90 (m, 1H), 5.95-6.05 (m, 2H), 7.02-7.06 (m, 2H), 7.51 (t, J = 4.2Hz , 4H), 7.51 (d, 1H), 11.51 (s, 1H) ; MS, m/e 557.99(M+1)+; 1136.84(2M+23)+

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 668 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
43	4-Me-Phe	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.16-1.24 (m, 6H), 2.22 (s , 3H), 3.65-4.03 (m,3H), 4.11-4.38 (m, 2H), 5.04-5.05 (m, 2H), 5.48-5.50 (m, 1H), 5.77-5.87 (m,1H),5.90-6.11 (m, 2H), 6.98-7.10 (m, 4H), 7.28-7.32 (m, 5H), 7.50 (t ,1H), 11.48 (s, 1H) ; MS, m/e 592.00 (M+1)+.
44	Ph	H	H	Et	Me	1H NMR (DMSO-d_6) δ 0.70-0.80 (m, 3H), 1.11-1.26 (m, 3H), 1.42-1.61 (m, 2H), 3.50-3.54 (m, 3H), 3.58-3.80 (m, 2H), 3.91-4.02 (m, 1H), 4.12-4.38 (m, 2H), 5.47-5.52 (m,1H),5.90-6.03 (m, 2H), 7.08-7.16 (m, 3H), 7.26-7.35 (m, 2H),7.48 (t,1H),11.45 (s, 1H) ; MS, m/e 515.95 (M+1)+; 1052.82 (2M+23)+
45	Ph	H	H	Me	4-F-Bn	^{1}HNMR (400MHz, DMSO-d_6): δ 1.20-1.26 (m, 6H), 3.80-3.93 (m, 2H), 3.98 (s, 1H), 4.25-4.26 (m, 1H), 4.36-4.37 (m, 1H), 5.07 (s, 2H), 5.52-5.55 (m, 1H), 5.86-5.87(m, 1H), 5.98-6.04 (m, 1H), 6.14-6.17 (m, 1H), 7.15-7.20 (m, 5H), 7.36 (dd, J = 20.0, 8.0 Hz, 4H), 7.54 (s, 1H), 11.55 (s, 1H)
46	4-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 1.21-1.28 (m, 6H), 3.71-3.88 (m, 1H), 3.91-3.98 (m, 1H), 4.00-4.01 (m, 1H), 4.23-4.27 (m, 1H), 4.35-4.38 (m, 1H), 5.08 (d, J = 4.0Hz, 2H), 5.57 (dd, J = 12.0, 8.0 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 6.01 (d, J = 8.0 Hz, 1H), 6.22-6.24 (m, 1H), 7.17-7.23 (m, 2H), 7.31-7.40 (m, 7H), 7.53 (s, 1H), 11.50 (s, 1H)
47	Ph	H	H	Me	3-Me-1-Bu	^{1}H NMR (DMSO-d_6) δ 0.80-0.82 (m, 6H), 1.18-1.40 (m, 8H), 1.50-1.58 (m, 1H), 3.71-3.82 (m, 3H), 3.97-3.4.01 (m, 3H), 4.21-4.40 (m, 2H), 5.30(t, J = 8.6 Hz, 1H), 5.81-6.10 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.48 (d, J = 8.4 Hz, 1H), 11.38 (s, 1H) ; MS, *m/e* 557.98 $(M+1)^+$; 1136.88 $(2M+23)^+$
48	3,4-diCl-Ph	H	H	Me	Bn	^{1}H NMR (DMSO-d_6) δ 1.05-1.37 (m, 6H), 3.71-3.82 (m, 1H), 3.87-4.02 (m, 2H), 4.28-4.29 (m, 1H),4.36-4.38 (m, 1H),5.04 (d, J = 5.2Hz, 2H), 5.55-5.64 (m, 1H), 5.85-5.94 (m, 1H), 6.00-6.05 (m, 1H), 6.29-6.40 (m, 1H),7.17-7.24 (m, 1H), 7.30-7.41 (m, 5H), 7.45-7.58 (m, 2H), 7.61 (d, J = 4.0Hz, 1H), 11.53 (s, 1H); MS, *m/e*545.80$(M+1)^+$;
49	Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.18-1.41 (m, 12H), 1.59-1.67 (m, 4H), 3.74-13.80 (m, 1H), 3.96-4.02 (m, 1H), 4.19-4.26 (m, 1H), 4.31-4.39 (m, 1H), 4.60 (s, 1H), 5.52 (t, J = 7.8 Hz, 1H), 5.80-6.09 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.52 (d, J = 8 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 569.98 $(M+1)^+$; 592.14 $(M+23)^+$
50	Ph	H	Me	H	n-Bu	1H NMR (DMSO-d_6) δ 0.76 (t, J = 7.2Hz, 3H), 1.10-1.22 (m, 8H), 1.38-1.43 (m, 2H), 3.72-3.75 (m, 2H), 3.87-3.93 (m, 3H), 4.14-4.21 (m, 1H), 4.23-4.33 (m, 1H), 5.46-5.54 (m, 1H), 5.84-6.11 (m, 3H), 7.09-7.14 (m, 2H), 7.27-7.32 (m, 2H), 7.34-7.51 (m, 1H), 11.47 (s, 1H); MS, m/e543.98(M+1)+
51	Ph	H	Me	H	i-Pr	1H NMR (DMSO-d_6) δ 1.39 (d, J = 7.2Hz, 6H), 1.19-1.29 (m, 6H), 3.65-3.75 (m, 2H), 3.95-4.05 (m, 1H), 4.20-4.22 (m, 1H), 4.31-4.33 (m, 1H), 4.79-4.82 (m, 1H), 5.48-5.57 (m, 1H), 5.84-5.91 (m, 1H), 5.96-6.07 (m, 2H), 7.12-7.35 (m, 5H), 7.44-7.54 (m.1H), 11.49(s, 1H); MS, m/e529.96 (M+1)+
52	Ph	H	Me	H	Bn	^{1}H NMR (DMSO-d_6) δ 1.18-1.28 (m, 6H), 3.70-3.83 (m, 1H), 3.87-3.94 (m, 1H), 3.99-4.01 (m, 1H), 4.23-4.26 (m, 1H), 4.33-4.37 (m,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 669 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						1H), 5.03-5.12 (m, 2H), 5.51-5.59 (m, 1H), 5.87-5.90 (m, 1H), 5.95-6.07 (m, 1H), 6.10-6.27 (m, 1H), 7.15-7.23 (m, 3H), 7.31-7.38 (m, 7H), 7.47-7.56 (m, 1H), 11.50 (s, 1H); MS, m/e577.99 (M+1)+
53	2-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 0.81-0.86 (m, 3H), 1.21-1.31 (m, 8H), 1.46-1.52 (m, 2H), 3.84-3.90 (m, 2H), 3.97-4.04 (m, 3H), 4.27-4.41 (m, 2H), 5.53-5.58 (m, 1H), 5.82-5.95 (m, 1H), 5.96-6.10 (m, 1H), 6.27-6.31 (m, 1H), 7.19-7.22 (m, 1H), 7.34 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.47-7.55 (m, 3H), 11.55 (s, 1H)
54	4-Br-Ph	H	H	Me	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ 1.10-1.14 (m, 6H), 1.20-1.27 (m, 6H), 3.74-3.81 (m, 2H), 3.99-4.01 (m, 1H), 4.21-4.25 (m, 1H), 4.37-4.38 (m, 1H), 4.81-4.85 (m, 1H), 5.58 (dd, *J* = 8.0, 4.0 Hz, 1H), 5.82-5.95 (m, 1H), 5.96-6.09 (m, 1H), 6.10-6.13 (m, 1H), 7.18 (dd, *J* = 12.0, 8.0 Hz, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H)
55	4-F-Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.20-1.44 (m, 12H), 1.60-1.71 (m, 4H), 3.75-4.02 (m, 2H), 3.94-4.02 (m, 1H), 4.19-4.26 (m, 2H), 4.59-4.61 (m, 1H), 5.57 (t, *J* = 8.4 Hz, 1H), 5.85-6.06 (m, 3H), 7.17-7.23 (m, 4H), 7.54 (d, *J* = 8.4 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 587.92 $(M+1)^+$
56	4-Br-Ph	H	H	Me	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ =1.18-1.46 (m, 12H), 1.61-1.69 (m, 4H), 3.75-3.82 (m, 2H), 3.95-4.08 (m, 1H), 4.25-4.28 (m, 1H), 4.38 (s, 1H), 4.60-4.62 (m, 1H), 5.56-5.60 (m, 1H), 5.82-5.95 (m, 1H), 6.02-6.20 (m, 2H), 7.09-7.20 (m, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H) MS, *m/e* 650.0 $(M+3)^+$
57	Ph	H	H	Et	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ =0.75-0.82 (m, 3H), 1.12-1.26 (m, 9H), 1.52-1.59 (m, 2H), 3.55-3.68 (m, 1H), 3.72-3.85 (m, 1H), 3.95-4.08 (m, 1H), 4.18-4.28 (m, 1H), 4.32-4.41 (m, 1H), 4.83-4.86 (m, 1H), 5.55 (m, *J*= 7.6Hz, 1H), 5.99-6.04 (m, 2H), 6.05-6.10 (m, 1H), 7.14-7.21 (m, 3H), 7.33-7.37 (m, 2H), 7.52-7.54 (m, 1H), 11.53 (s, 1H) ; MS, *m/e*566.07$(M+23)^+$
58	Ph	H	H	Et	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ 0.75-0.88 (m, 3H), 1.26-1.46 (m, 9H), 1.52-1.69 (m, 6H), 3.60-3.63 (m, 1H), 3.72-3.90 (m, 1H), 4.02-4.03 (m, 1H), 4.24-4.27 (m, 1H), 4.37-4.38 (m, 1H), 4.63-4.65 (m, 1H), 5.55 (dd, *J* =8.0Hz, 4.4Hz, 1H), 5.80-5.95 (m, 1H), 6.00-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.34-7.38 (m, 2H), 7.54 (d, *J* =8.0Hz, 1H), 11.55 (s, 1H); MS, *m/e* 584.01 $(M+1)^+$, 606.17 $(M+23)^+$
59	4-F-Ph	H	H	Et	c-Hex	^{1}H NMR (DMSO-d_6) δ 0.75-0.84 (m, 3H), 1.24 (d, *J* = 22.8Hz, 3H), 1.29-1.47 (m, 6H), 1.51-1.70 (m, 6H), 3.59-3.66 (m, 1H), 3.77-3.84 (m, 1H), 3.98-4.04 (m, 1H), 4.21-4.27 (m, 1H), 4.34-4.41 (m, 1H), 4.60-4.65 (m, 1H), 5.56-5.60 (m, 1H), 5.84-5.90 (m, 1H), 6.00-6.08 (m, 2H), 7.20-7.24 (m, 4H), 7.56(d, *J* = 8.0Hz, 1H), 11.49 (s, 1H); MS, *m/e* 602.00$(M+1)^+$
60	Ph	H	H	Me	F-CH_2-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.18-1.25(m, 6H), 3.71-3.89 (m, 2H), 3.92-3.99 (m, 1H), 4.19-4.27 (m, 4H), 4.48-4.61 (m, 2H) , 3.94-3.98 (m, 2H), 4.11-4.23 (m, 4H), 5.47-5.52 (m, 1H), 6.01-6.11 (m, 1H), 5.90-6.14

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 670 of 739

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						(m, 2H), 7.15-7.21 (m, 3H), 7.32-7.36 (m, 2H), 7.46-7.57 (m, 1H), 11.49 (s,1H) ; MS, *m/e* 533.86 $(M+1)^+$
61	Ph	H	H	Me	F_2CH-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.17-1.24 (m, 6H), 3.67-3.81 (m, 1H), 3.89-3.98 (m, 2H),4.21-4.36 (m, 4H), 5.48-5.53 (m, 1H) , 5.82-6.05 (m, 2H), 6.18-6.22 (m, 2H), 7.15-7.20 (m, 3H), 7.32-7.36 (m , 2H), 7.51 (s, 1H),11.50 (s, 1H) ; MS, *m/e* 551.92 $(M+1)^+$;
62	Ph	H	H	Me	$(CF_3)_2$-CH-	^{1}H NMR (DMSO-d_6) δ 1.13-1.29 (m, 6H), 3.67-3.81 (m, 1H), 3.94-4.32 (m, 4H), 5.47 (t, *J* = 8 Hz 1H) , 5.82-6.01 (m, 2H), 6.33-6.36 (m, 1H), 6.70-6.78 (m, 1H), 7.09-7.15 (m, 3H), 7.28-7.32 (m , 2H), 7.43-7.46 (m, 1H),11.44 (s, 1H) ; MS, *m/e* 637.90 $(M+1)^+$
63	Ph	H	H	Me	$(CH_2F)_2$ -CH-	^{1}H NMR (DMSO-d_6) δ 1.20-1.29 (m, 6H), 3.70-3.90 (m, 1H), 3.91-4.12 (m, 2H), 4.20-4.33 (m, 1H), 4.35-4.48 (m, 1H), 4.52-4.55 (m, 2H) , 4.63-4.67 (m, 2H), 5.20-5.35 (m, 1H), 5.56 (t, *J* = 8.4 Hz, 1H), 5.80-5.95 (m, 1H), 5.95-6.10 (m, 1H), 6.18-6.21 (m, 1H), 7.18-7.23 (m, 3H), 7.35-7.39 (m , 2H), 7.54 (s, 1H),11.55 (s, 1H) ; MS, *m/e* 565.98 $(M+1)^+$
64	Ph	H	H	Me	c-Pr-CH_2-	^{1}H NMR (DMSO-d_6) δ 0.20-0.24(m, 2H), 0.47-0.48(m, 2H), 0.76-0.84(m, 3H), 1.03-1.05(m, 1H), 1.23(dd, *J= 22.4 6.8 Hz* 3H), 1.55-1.60(m, 2H), 3. 61-3.68(m, 1H), 3. 81-3.89 (m, 3H), 3.98-4.03(m, 1H), 4.23-4.29(m, 1H), 4.35-4.41(m, 1H), 5.56-6.00(m, 1H) , 5.88-5.91(m, 1H), 6.04-6.10(m, 2H), 7.20-7.24(m, 4H), 7.55 (d, *J= 7.6 Hz* 1H),11.53 (s, 1H) ; MS, *m/e* 573.17 $(M+1)^+$
65	Ph	H	H	Et	c-Pen	^{1}H NMR (DMSO-d_6) δ 0.75-0.83 (m, 3H), 1.20-1.28 (m, 3H), 1.49-1.63 (m, 8H), 1.76-1.80 (m, 2H), 3.58-3.60 (m, 1H), 3.70-3.82 (m, 1H), 3.98-4.05 (m, 1H), 4.24-4.26 (m, 1H) , 4.37-4.42 (m, 1H), 5.03 (s, 1H), 5.54-5.57 (m, 1H), 5.90-6.00 (m,1H), 6.02-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.35-7.39 (m, 2H) 7.55 (d, *J* = 8.0 Hz, 1H), 11.55 (s, 1H) ; MS, *m/e* 570.03 $(M+1)^+$

*R^2 and R^{3b} together are $-(CH_2)_3-$ as derived from L-proline

The purification procedure by Prep-HPLC:

Crude products were dissolved in methanol. Injection volumes of these solutions were 5 mL.

The preparative HPLC system including 2 sets of Gilson 306 pumps, a Gilson 156 UV/Vis detector, a Gilson 215 injector & fraction collector, with Unipoint control software. A Ymc 25×30×2 mm column was used. The mobile phase was HPLC grade

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 671 of 739

water (A), and HPLC grade acetonitrile (B). Fractions were collected into 100*15mm glass tubes.

HPLC gradient is shown in Table 1. Once the gradient was selected, acetonitrile solution was injected into HPLC system, and then fractions collected according to UV peaks. After the separation, each glass tubes were run MS test to collect the desired compounds. The fractions with target MS were combined in a well-weighted flask. Most of acetonitrile was removed under reduce pressure and the remaining solution was freeze-dried to give desired compound.


Table 1:

Preparative HPLC gradient			
Time (min)	Flow rate (mL/min)	% A	% B
0	15	90	10
30	15	60	40

Preparation of Example 66

Scheme

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 672 of 739



Preparation of compound (b)

To a solution of compound **a** (1 g, 2.69 mmol) in anhydrous THF (30 mL) was added dropwise 1 M solution of $LiAl(OBu\text{-}t)_3H$ in THF (2.69 mL, 2.69 mmol) at -20 °C. The reaction mixture was stirred for 2-3 h at the same temperature. EtOAc (100 mL) was added followed by saturated NH_4Cl solution (10 mL) and reaction mixture was slowly brought to room temperature. Reaction mixture was extracted with EtOAc and washed with 1N HCl and water. Combined organic phase was evaporated to give 0.8 g of crude compound **b** as transparent oil, which was used directly for next reaction.

Preparation of compound (d)

To a solution of compound **b** (0.8 g, 2.1mmol), compound **c** (0.45 g, 2.5 mmol) and Ph_3P (0.56 g, 2.1 mmol) in anhydrous THF (20 mL) under nitrogen atmosphere was added DEAD (1.8 mL). The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduce pressure. The residue was separated

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 673 of 739

by preparative layer chromatography (hexanes:EtOAc = 3:1) to give crude compound **d** (0.8 g). The crude compound **d** was used to the next step without further purification.

Preparation of compound (e)

Compound **d** (0.8 g, 1.57 mmol) was dissolved in THF (2 mL) and THF saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was heated to 90 °C overnight. After 18 hours, the solution was cooled to room temperature by ice water, then the solvent was removed under reduced pressure and the residue was purified by column to give compound **e** (0.75 g) for the next step.

Preparation of compound (f)

Compound **e** (0.5 g, 1.01 mmol) was dissolved in methanol (2 mL) and methanol was saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was stirred at room temperature overnight. After 18 hours, the solvent was removed under reduced pressure and the residue was purified by column to give crude compound **f** (0.15 g) for the next step.

Preparation of compound (i)

A solution of triethylamine (1.07 g, 10.6 mmol) in anhydrous dichloromethane (15 mL) was added dropwise to a solution of compound **g** (1.16 g, 5.3 mmol) and compound **h** (1.31 g, 5.3 mmol) in dichloromethane (10 mL) with vigorous stirring at -78 °C over a period of 2 hours. After completion of addition, the reaction temperature was allowed to warm to room temperature gradually and stirred over night. Then the solvent was removed under vacuum and anhydrous ether 20 mL was added and the precipitated salt was filtered and the precipitate was washed with ether. The combined organic phase was concentrated to give the colorless oil of compound **i** (1.0 g).


Preparation of Compound 66


To a solution of compound **j** (0.1 g, 0.35 mmol) dissolved in 10 mL of anhydrous THF, stirred and added 0.4g NMI till the solution became clear, added compound **i** (0.8 g, 2.89 mmol) in 10 mL THF dropwise, stirred at r.t. overnight. Compound purity and identification was confirmed by LCMS. The solvent was evaporated and purified by Prep-HPLC to afford **66**. (25 mg, Yield: 13.6%). ^{1}H NMR (DMSO-d_6) δ 1.08 (d, J = 22.8 Hz, 3H), 1.17-1.24 (m, 3H), 3.50-3.52 (m, 3H), 3.78-3.83 (m, 1H), 4.10-4.13 (m,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 674 of 739


1H), 4.24-4.44 (m, 2H), 5.85-5.92 (m, 1H), 6.01-6.11 (m,1H), 6.2.-6.27 (m, 1H), 7.08-7.19 (m, 4H), 7.31-7.38 (m, 3H), 8.15 (s, 1H), 8.26 (s, 1H); MS, *m/e* 525 $(M+1)^+$.

Example numbers **67-74**, identified below, were prepared using similar procedures disclosed for Example **66**, above.




Example	R^{11}	R^{10}	NMR/MS
67	OH	NH_2	^{1}H NMR (DMSO-d_6) δ 1.06-1.13 (m, 3H), 1.20-1.24 (m, 3H), 3.27-3.33(m, 3H), 3.56 (s, 1H), 3.82-3.88 (m, 1H), 4.07-4.13 (m, 1H), 4.25-4.40 (m, 2H), 5.85-5.87 (m, 1H), 5.98-6.09 (m, 2H), 6.59 (s, 32H), 7.14-7.37 (m, 3H), 7.35-7.37 (m, 2H), 7.79 (d, *J*=7.2 Hz, 1H), 10.69 (s, 1H); MS, *m/e* 541 $(M+1)^+$;
68	NH_2	NH_2	^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.8 Hz, 3H), 1.19 (d, *J*=7.2 Hz, 3H), 3.51 (s, 3H), 3.62 (s, 1H), 3.75-3.81 (m, 1H), 4.05-4.11 (m, 1H), 4.27-4.42 (m, 2H), 5.79-5.83 (m, 1H), 5.92 (s, 2H), 6.00-6.09 (m, 2H), 6.75 (s, 2H), 7.08-7.17 (m, 3H), 7.31-7.35 (m, 2H), 7.78 (s, 1H); MS, *m/e* 540 $(M+1)^+$;
69	NH_2	c-Pentyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.05 (d, *J*=22.8 Hz, 3H), 1.09-1.19 (m, 3H), 1.48 (s, 4H), 1.66 (s, 1H), 1.86 (s, 1H), 3.54 (d, *J*=14 Hz, 3H), 3.65 (s, 1H), 4.25-4.43 (m, 4H), 5.71-5.82 (m, 1H), 5.94-6.04 (m, 4H), 7.11-7.24 (m, 3H), 7.26-7.34 (m, 2H), 7.77(d, *J*=3.6 Hz, 1H); MS, *m/e* 608$(M+1)^+$
70	NH_2		^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.4 Hz, 3H), 2.35-2.38 (m, 2H), 3.54 (d, *J*=9.2 Hz, 3H), 3.59-3.62 (m, 2H), 3.65 (s, 1H), 3.75-3.82 (m, 1H), 4.01-4.13 (m, 2H), 4.22-4.40 (m, 6H), 5.75-5.85 (m, 1H), 6.00-6.07 (m, 4H), 7.15-7.21 (m, 3H), 7.32-7.35 (m, 2H), 7.79 (d, *J*=4.0 Hz, 1H); MS, *m/e* 580 $(M+1)^+$
71	NH_2	Et_2N-	^{1}H NMR (DMSO-d_6) δ 1.06-1.28 (m, 12H), 3.55 (d, *J*=4.8 Hz, 3H), 3.79-3.87 (m, 4H), 4.07-4.12 (m, 2H), 4.29-4.42 (m,




Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 675 of 739

Example	R^{11}	R^{10}	NMR/MS
			3H), 5.75-5.82 (m, 1H), 5.94 (s, 2H), 6.04-6.10 (m, 2H), 7.14-7.22 (m, 3H), 7.31-7.37 (m, 2H), 7.82 (d, *J*=4.4 Hz, 1H); MS, *m/e* 596 $(M+1)^+$
72	NH_2	n-Propyl-NH-	^{1}H NMR (DMSO-d_6) δ 0.84 (t, *J*=7.2 Hz, 3H), 1.01-1.01 (m, 3H), 1.09-1.12 (m, 3H), 1.51-1.56 (m, 2H), 3.48 (d, *J*=15.2 Hz, 3H), 3.79-3.82 (m, 1H), 4.04-4.05 (m, 1H), 4.27-4.38 (m, 3H), 5.72-5.79 (m, 1H), 5.98-6.04 (m, 4H), 7.13-7.20 (m, 3H), 7.26-7.32 (m, 2H), 7.76 (d, *J*=5.2 Hz, 1H); MS, *m/e* 582 $(M+1)^+$
73	NH_2	c-Butyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.02-1.08 (m, 3H), 1.18 (d, *J*=4.8 Hz, 3H), 1.44-1.61 (m, 2H) , 2.02-2.17 (m, 4H), 3.51 (d, *J*=10.8 Hz, 3H), 3.78-3.83 (m, 1H), 4.03-4.06 (m, 1H), 4.27-4.38 (m, 2H), 4.53-4.62 (m, 1H), 5.68-5.79 (m, 1H), 5.95-6.04 (m, 4H), 7.11-7.18 (m, 3H), 7.29-7.35 (m, 2H), 7.51-7.58 (m, 1H), 7.78 (d, *J*=5.2 Hz, 1H); MS, *m/e* 594 $(M+1)^+$
74	NH_2		^{1}H NMR (DMSO-d_6) δ 0.97-1.20 (m, 6H), 2.18 (s, 3H), 2.19 (s, 4H), 3.43-3.47(m, 3H), 3.75 (s, 1H), 4.01-4.06 (m, 4 H), 4.22-4.35 (m, 3H), 5.69-5.75 (m, 1H), 5.98-6.05 (m, 3H), 7.09-7.15 (m, 3H), 7.25-7.29 (m, 2H), 7.77 (d, *J*=3.6 Hz, 1H); MS, *m/e* 623 $(M+1)^+$

Example numbers 75-80 are prepared using similar procedures disclosed for Example **66**, above.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 676 of 739



Example	R^{11}	R^{10}
75	H	n-propyl-NH-
76	H	c-Butyl-NH-
77	H	c-Pentyl-NH-
78	H	
79	H	
80	H	

EXAMPLE 81

Certain exemplified compounds were obtained as mixture of diastereomers because of the chirality at phosphorous. The diastereomers were separated on a Chiralpak-AS-H (2 X 25 cm) column under Supercritical Fluid Chromatography (SFC) conditions using 20% methanol in carbon dioxide as solvent. The absolute stereochemistry of the P-chiral center of the diastereromers were not determined. However, chromatographic resolution of these two diastereomers provides for isomers that are characterized as fast eluting and slow eluting isomers. Some examples are shown below.

Compound	**EC90 (uM)**
Example 15 (Diastereomeric mixture)	0.86
Fast Moving isomer of **Example 15**	1.35
Slow Moving isomer of **Example 15**	0.26

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 677 of 739

Compound	EC90 (uM)
Example 39 (Diastereomeric mixture)	0.47
Fast Moving isomer of **Example 39**	0.78
Slow Moving isomer of **Example 39**	0.02
Example 49 (Diastereomeric mixture)	0.126
Fast Moving isomer of **Example 49**	0.03
Slow Moving isomer of **Example 49**	5.78







EXAMPLE 82

HCV replicon assay. HCV replicon RNA-containing Huh7 cells (clone A cells; Apath, LLC, St. Louis, Mo.) were kept at exponential growth in Dulbecco's modified Eagle's medium (high glucose) containing 10% fetal bovine serum, 4 mM L-glutamine and 1 mM sodium pyruvate, 1× nonessential amino acids, and G418 (1,000 μg/ml). Antiviral assays were performed in the same medium without G418. Cells were seeded in a 96-well plate at 1,500 cells per well, and test compounds were added immediately after seeding. Incubation time 4 days. At the end of the incubation step, total cellular RNA was isolated (RNeasy 96 kit; Qiagen). Replicon RNA and an internal control (TaqMan rRNA control reagents; Applied Biosystems) were amplified in a single-step multiplex RT-PCR protocol as recommended by the manufacturer. The HCV primers and probe were designed with Primer Express software (Applied Biosystems) and covered highly conserved 5′-untranslated region (UTR) sequences (sense, 5′-AGCCATGGCGTTAGTA(T)GAGTGT-3′, and antisense, 5′-TTCCGCAGACCACTATGG-3′; probe, 5′-FAM-CCTCCAGGACCCCCCCTCCC-TAMRA-3′).







To express the antiviral effectiveness of a compound, the threshold RT-PCR cycle of the test compound was subtracted from the average threshold RT-PCR cycle of the no-drug control (ΔCt_{HCV}). A ΔCt of 3.3 equals a 1-log 10 reduction (equal to the 90%

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 678 of 739








effective concentration [EC_{90}]) in replicon RNA levels. The cytotoxicity of the test compound could also be expressed by calculating the ΔCt_{rRNA} values. The $\Delta\Delta Ct$ specificity parameter could then be introduced ($\Delta Ct_{HCV} - \Delta Ct_{rRNA}$), in which the levels of HCV RNA are normalized for the rRNA levels and calibrated against the no-drug control.

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11
10		-1.25	19.15
11		-0.55	ND

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 679 of 739

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
12		0.31	ND
15		ND	0.86
25		-2.22	0.39
27		-2.25	0.66
28		-2.16	0.75
36		-1.64	21.9

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 680 of 739

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
39		-1.78	0.47
49		-2.69	0.126
53		-1.33	<0.3
54		-1.55	0.57
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 681 of 739


[1](4-BrPh): 4-bromo-phenyl.

The entire contents of U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, are hereby incorporated by reference in the present application so far as needed to supplement the present disclosure and/or rectify any errors. Moreover, the patent and non-patent references disclosed herein are incorporated by reference. In the event that the incorporated patent and non-patent reference contains a term that conflicts with a term disclosed in either one of the two Provisional Applications or the present application text, the meaning of the term contained in the present application text and the two Provisional Applications controls provided that the overall meaning of the incorporated subject matter is not lost.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 682 of 739

We claim:

1. A compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 683 of 739

includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl,substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 684 of 739

alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 685 of 739

C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

2. A compound its stereoisomer, salt, hydrate, solvate, or crystalline form thereof selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 686 of 739

pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 687 of 739

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 688 of 739

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 689 of 739

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 690 of 739

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

3. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 691 of 739

by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 692 of 739

to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl),

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 693 of 739

$SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 694 of 739

C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted $C_{1\text{-}20}$ alkyl, an optionally substituted $C_{1\text{-}10}$ alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)($C_{1\text{-}20}$ alkyl), C(O)($C_{1\text{-}10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

4. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 695 of 739

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 696 of 739

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 697 of 739

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 698 of 739

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 699 of 739

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 700 of 739

5. A use of the compound represented by formula I in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

wherein the compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, are represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 701 of 739

group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 702 of 739

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 703 of 739

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) –C=CH_2, or (iii) –NO_2.

6. A use of

a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 704 of 739

hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 705 of 739

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 706 of 739

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 707 of 739

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 708 of 739

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 709 of 739


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

7. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of the compound represented by formula I to the subject;

wherein the compound or its stereoisomer, salt, hydrate, solvate, or crystalline form thereof represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 710 of 739

which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or -$N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, -$(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, -CH_2SH, -$(CH_2)_2S(O)_dMe$, -$(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -$(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or –$N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, -CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 711 of 739

cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 712 of 739



a b c d

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 713 of 739

$CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

8. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 714 of 739

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 715 of 739

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 716 of 739

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 717 of 739

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 718 of 739

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

9. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 719 of 739

which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or -$N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 720 of 739

cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-10} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{2-4} alkynyl), C(O)O(C_{2-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 721 of 739



a b c d

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 722 of 739


$CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$;

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

10. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 723 of 739

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 724 of 739

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 725 of 739

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 726 of 739

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 727 of 739

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4




5


11. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 728 of 739

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 729 of 739

$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN,

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 730 of 739

one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R',

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 731 of 739

alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) $–C{=}CH_2$, or (iii) $–NO_2$

and


wherein X' is a leaving group, such as, Cl.

12. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5 ;

wherein the product comprises a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 732 of 739

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 733 of 739

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 734 of 739

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 735 of 739

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 736 of 739

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 737 of 739

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate


wherein Base' is as recited in each of compounds 5-74; and

wherein X' is a leaving group, such as, Cl.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 738 of 739

ABSTRACT

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:



I

Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula **I**.

Atea Pharmaceuticals, Inc.
Exhibit 1011 Page 739 of 739